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 Cardiovascular disease is the leading cause of death in developed countries, but we lack 
the ability to regenerate cardiac tissue. Cell-based therapy holds promise to repopulate a 
damaged heart with functional cardiomyocytes. Developing technologies to produce cells for 
transplantation is key to the success of this approach. Pluripotent stem cells (PSC) are an ideal 
starting material for cell-based therapies because they can be expanded indefinitely in culture 
and their plasticity gives them the potential to regenerate any tissue or organ. The issue of 
teratoma formation in the host may be avoided by devising methods to differentiate PSC toward 
a desired lineage before transplantation. Because the heart is vital for life, and the biggest source 
of human morbidity and mortality, in vitro differentiation of PSC into cardiomyocytes for cell-
based treatment of heart disease is an area of intense research.   
Exogenous expression of vital cardiogenic genes in PSC can be a powerful tool. 
Transduction of PSC with recombinant viral vectors can deliver genes to activate cardiac 
programming and drive differentiation toward a cardiac lineage. Replication defective HSV 
vectors efficiently transduce PSC and can be engineered to express genes that alter the cellular 
differentiation program. The goal of this research was to develop highly defective HSV vectors 
to express multiple cardiac transcription factors in embryonic stem cells to increase their 
cardiogenic potential. Vectors vββG4Nk, vG4Nk, and vGTM were engineered to express GATA4 
and NKX2.5 or GATA4, TBX5, and MEF2c in PSC with high efficiency and low toxicity. 
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Transduction of mESC with these vectors induced the expression of endogenous genes that are 
vital for cardiogenesis. Differentiation of mESC transduced with cardiogenic HSV vectors had a 
positive impact on terminal cardiomyocyte differentiation, producing many more embryoid 
bodies with beating cardiomyocytes than those transduced with control vectors. In addition, we 
found that delaying the drastic dilution of viral genomes that occurs over the time interval to 
terminal differentiation could enhance the outcome. Our results indicate that infection of mESC 
with cardiogenic HSV vectors has long reaching effects on mESC differentiation, supporting the 
suggestion that HSV vectors can be a useful tool for producing lineage related changes in 
differentiating PSC to generate specialized cell types. 
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1.0  INTRODUCTION 
 
1.1 CARDIAC DEVELOPMENT 
The heart is the first organ to function during embryonic development. From the earliest stages 
of embryogenesis through adulthood, the life of all animals depends on uninterrupted cardiac 
function. The cellular and molecular events that occur during heart development, and its function 
and gene expression through adulthood, are highly conserved among mammals. Specific 
manipulations in mice, including gene knockouts, reporter genes to define differentiation related 
events, cell grafts to evaluate cellular function, and explant cultures to examine molecular 
genetics, are used to elucidate the events involved in mammalian cardiogenesis. Understanding 
the development and operation of the heart is vital for learning about the pathology of and 
devising treatments for congenital and acquired cardiac diseases. Following gene expression and 
cell signaling patterns through the earliest stages of embryonic cardiogenesis all the way to 
committed heart cell types in vivo enables us to influence these events in vitro to generate 
cardiomyocytes from pluripotent stem cells or, more recently, to transdifferentiate other 
committed cell types into cardiomyocytes both in vitro and in vivo.  
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1.1.1 Embryonic cardiogenesis 
Commitment of a subset of embryonic cells to cardiogenesis is one of the earliest events to occur 
in a developing embryo. Cell fate mapping experiments in mouse embryos demonstrated that 
cardiac precursor cells are found prior to gastrulation, a process that begins with the appearance 
of the primitive streak (PS) around mouse embryonic day E5 (1). Brachyury expression marks 
PS formation (2), which establishes bilateral symmetry in the embryo and determines the site of 
gastrulation, the formation of the three germ layers (endoderm, mesoderm, and ectoderm). 
Timing and location of cellular ingression through the PS determines the fate of gastrulating 
cells. A subset of epiblast cells moves as a sheet through the PS, undergoing epithelial-to-
mesenchymal transition and forming the mesendoderm. Cardiac mesoderm progenitors migrate 
to an anterior lateral region relative to the PS to form the splanchnic mesoderm. At mouse 
embryonic day E7.5 (roughly week 2 of human gestation), these mesodermal cells underlying the 
head folds, called the first heart field (FHF), form the cardiac crescent (3). The crescent fuses at 
the midline on E8 (3 weeks human gestation) to form the beating cardiac tube, which then 
undergoes a rightward looping and rapid growth to form an S-shaped structure. The cardiac 
crescent grows through cell proliferation and recruitment of additional cells called the secondary 
heart field (SHF) (4), and undergoes a series of rearrangements that ultimately leads to the 
formation of the recognizable four-chambered septated heart by E14.5 (approximately 7 weeks 
human gestation).  
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Figure 1. Formation of the cardiac crescent and rearrangements to form the embryonic heart  
The cardiac crescent forms at the cranial side of the 7.5 day old mouse embryo. Contributions from the 
first heart field are shown in red and the second heart field in blue. Cr – cranial; Ca – caudal; R – right; L 
– left. 
 
 
 
Following septation, the heart chambers continue to grow while complex differentiation 
programs take place to generate the additional smooth muscle cells, pacemakers, fibroblasts, 
cardiomyocytes, endothelial cells, and conducting cells that compose the mature heart (5). 
1.1.2 Molecular events driving cardiogenesis 
Cardiac lineage specification is initially driven largely by a gradient of signaling molecules 
established very early during embryogenesis. Transforming growth factor (TGF)β family 
members Nodal and Activin work together with the Wnt/β-catenin pathway to specify the 
formation of the mesendoderm in developing embryos (6). Bone morphogenetic protein (BMP)2, 
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another TGFβ family member, is vital for the induction of cardiac mesoderm (7), and BMP2-
deficient mice are non-viable, suffering from severe cardiac defects (8). The critical balance 
between BMP2 and Nodal is tightly regulated by Wnt/β-catenin signaling in the PS (Figure 2). 
Dysregulation of the BMP/Smad vs. Nodal balance causes a defect in the laterality in the heart-
forming region (9).  
 
 
 
 
 
 
Figure 2. BMP and Wnt expression in the early embryo 
Around mouse embryonic day E5, gradients of BMP, Wnt, and Wnt inhibitors form to create the 
primitive streak (PS) and initiate cardiogenesis in the correct location of the developing embryo. BMP 
induces formation of the precardiac mesoderm while Wnt inhibits cardiac formation in other parts of the 
embryo. 
 
 
 
The proximal-distal gradient of Nodal/Smad plays a vital role in the segregation of the endoderm 
and mesoderm and regulates expression of the transcription factors OCT4 and EOMES (10). 
OCT4 is vital for cardiac specification and targets SOX17, another transcription factor required in 
early cardiogenesis (11). The first mesodermal lineage to emerge expresses the transmembrane 
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receptor VEGF-R2 (mouse gene Flk-1, human gene KDR) in response to BMP4 signaling, which 
also induces expression of the zinc finger transcription factors GATA4/5/6 in the precardiac 
mesoderm (12). GATA4 is widely regarded as the master regulator of cardiogenesis, binding to 
the promoters of many cardiac-specific genes to switch on their expression, and GATA4 null 
mice do not develop a heart and die in utero (13). GATA4 is expressed in the embryonic 
myocardium throughout development and into adulthood (Figure 4) (14). GATA sites are 
frequently present along with Smad sites on the enhancers of cardiac genes, including the early 
expressed NKX2.5, underscoring the vital role of BMP signaling in embryonic cardiac 
development (Figure 3) (15). Introduction of the BMP antagonist Noggin to pre-cardiac 
mesoderm inhibits cardiomyogenesis and expression of cardiac marker genes GATA4, NKX2.5, 
MEF2A, eHAND, and VMHC1 (7).  
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Figure 3. Cardiac gene transcription is activated through BMP/Smad signaling  
BMP expression and signaling in the developing embryo is vital for embryonic patterning and formation 
of the heart. BMPs form active dimers and bind to BMP receptors (BMPR), driving the formation of the 
ternary complex consisting of two type 1 and two type 2 BMP receptor subunits and their bound BMPs. 
Type 2 BMPRs phosphorylate type 1 BMPRs, which in turn phosphorylate and activate R-Smad. 
Phosphorylated R-Smad forms a complex with Co-Smad that is transported to the nucleus where it binds 
to promoters/enhancers and activates the transcription of cardiogenic genes.  
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As Flk-1/KDR expression decreases, the mesoderm is patterned into distinct subsets and 
mesoderm posterior 1 (Mesp1) is expressed. Mesp1 functions to promote activation of the 
cardiogenic transcriptional network as mesodermal cells ingress through the PS (16). The cardiac 
crescent begins to organize and FHF progenitors begin to differentiate into committed 
myocardial cell types through their exposure to cytokines of the BMP (17) and FGF (18) families 
and inhibitors of the Wnt pathway (19). Expression of T-box transcription factor 5 (Tbx5) and 
contractile proteins like myosin light chain-2a (MLC2a) follows as the linear heart tube forms 
and begins to beat.  
The SHF, marked by expression of the LIM-homeodomain transcription factor ISL1, is 
activated through FGF, SHH, and canonical Wnt signaling (20). ISL1 function is required for 
proliferation and migration of SHF cells to the primitive heart tube, and its expression is 
suppressed as the cardiac progenitor cells reach the developing heart and begin to differentiate in 
response to BMP, Notch, and non-canonical Wnt signaling (21). 
As the heart tube begins to loop and rearrange to form its four septated chambers, 
transcription of a whole host of other transcription factors and cardiac-specific genes is initiated 
by GATA4, MESP1, HAND2, NKX2.5, MEF2C, MYOCD, and TBX5 among others. These 
transcription factors give rise to the expression of all of the structural and functional cardiac 
proteins, including cardiac troponin T, α-myosin heavy chain (α-MHC), myosin light chain 2a 
and 2v, and α-actinin.  
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Figure 4. Key regulators of embryonic cardiomyogenesis  
Expression of cardiac transcription factors at different times throughout heart formation guide the 
differentiation of cardiac progenitors into specialized cardiac cell types. Cr – cranial; Ca – caudal; R – 
right; L – left. 
 
1.2 CARDIOVASCULAR DISEASE  
Cardiovascular disease (CVD) remains the largest cause of global morbidity and mortality, 
particularly in developed nations. One American dies from CVD every 40 seconds with a total 
annual cost in the United States of an estimated $315.4 billion, over $100 billion more than all 
cancers and benign neoplasms combined (22). While CVD encompasses a wide range of medical 
problems relating to the cardiovascular system, ischemic heart disease, a restriction of blood 
flow to the heart, is by far the most pervasive (22). Myocardial infarction (MI) is typically a 
result of atherosclerosis, the build-up of plaque, causing blockage of the coronary arteries. The 
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resulting loss of blood flow permanently damages the patient’s heart, leading to arrhythmia, 
chronic heart disease, and sometimes death. Unlike many organs, the adult mammalian heart 
lacks significant inherent regenerative capacity (23). During a large MI, 108 to 109 functional 
cardiomyocytes are lost to apoptosis or necrosis (24) and the function of the post-infarcted heart 
deteriorates over time (25). The lost cells are replaced by scar tissue consisting mainly of 
fibroblasts that do not contribute to and further inhibit cardiac function. Advances have been 
made in the treatment of ischemic heart disease, including the use of angiotensin-converting 
enzyme (ACE) inhibitors and β-adrenergic blockers to improve cardiac function (26). Left 
ventricular assist devices (LVAD) can act as a bridge treatment to heart transplant, or as a 
destination treatment in patients who are terminally ill and/or do not qualify for transplantation, 
by pumping blood out of the left ventricle to support normal circulation (27). While currently 
available treatments improve the prognosis and quality of life for patients suffering from heart 
disease, they lack the ability to regenerate the functional cardiac tissue that has been damaged or 
lost. The only currently established method to cure a patient with severe heart damage is heart 
transplantation, an option that is not viable in most cases due to poor overall health of the patient, 
the extremely limited availability of donor organs, and the requirement for lifelong intense 
immunosuppressive therapy following transplant. Cell-based therapy for the treatment of CVD is 
a promising alternative, and has become an increasingly popular area of study in recent years. 
Cell-based therapy aims to repopulate a damaged heart with functional cardiomyocytes to 
physically heal the heart instead of merely alleviating the symptoms of CVD. Laboratories have 
published data on transplantation of numerous different cell types into animal models and later 
humans who have suffered myocardial infarction (MI) with mixed and often conflicting results. 
There are many variables that must be considered before cell-based therapy can become a 
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standard treatment for diseased and damaged hearts, and careful consideration of the data with 
longer-term follow-up is an absolute necessity. For example, Laflamme et al. reported significant 
improvement in cardiac function after four weeks in a rat model of MI upon injection of hESC-
derived cardiomyocytes (28), but Mummery et al. followed a similar protocol in mice with a 
three month follow-up, and found that while at four weeks the transplanted cells survived and 
significantly improved cardiac function, by three months there was no significant functional 
improvement (29). 
The type of cells transplanted is a critical factor in the ultimate success of the cell-based 
approach to treatment of CVD. Early studies focused on transplantation of committed cells with 
promising results, including skeletal myoblasts (30) and fetal cardiomyoblasts (31), but these 
types of cells are limited in availability and not practical for extensive clinical use, leading focus 
to shift towards stem cells and their derivatives. 
1.3 STEM CELLS 
Stem cells possess two defining characteristics: the ability to self renew, or divide symmetrically 
to create new stem cells, and the ability to divide asymmetrically to differentiate into other cell 
types, either into further lineage committed progenitor cells or into terminally differentiated 
mature cell types. Stem cells can be derived from embryonic tissue (embryonic stem cells, ESC), 
created through reprogramming of differentiated cell types (induced pluripotent stem cells, 
iPSC), and found in many organs throughout the adult body. While ESC and iPSC are 
pluripotent, or able to differentiate into any cell type in the body, adult stem cells are more 
lineage restricted and considered to be multipotent. More recently, the considerable plasticity of 
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adult stem cells has been recognized as they are transplanted into other niches and give rise to 
cell types beyond their perceived lineage restriction (32-35). 
1.3.1 Adult stem cells and cardiac regenerative therapy 
Also known as somatic stem cells, adult stem or progenitor cells are a small sub-population of 
cells that reside in many tissues and organs throughout the body. They collectively give rise to a 
large family of descendants with many types of specialized phenotypes that are capable of 
renewing and repairing organs and tissues. These cells are an attractive option for use in cell-
based therapies because they can be autologously derived and have the potential to differentiate 
into many lineages when transplanted outside of their niche. Bone marrow in particular contains 
a relatively large reservoir of both hematopoietic stem cells (HSC) and mesenchymal stem cells 
(MSC). MSC are a useful cell type for regenerative medicine because they are easily expanded in 
vitro and can form bone, cartilage, tendon, muscle, and fat cells (36). MSC have been shown to 
transdifferentiate into cardiomyocytes in culture in the presence of 5-azacytidine (37) or when 
co-cultured with cardiomyocytes (38, 39). Other types of adult stem cells include satellite cells 
that are responsible for the maintenance of muscle fibers (40), epidermal and follicular stem cells 
that reside in the apical portion of hair follicles and give rise to skin, hair, sebaceous glands, and 
sweat glands (41, 42), and several types of endodermal stem cells that reside near the bottom of 
each gut crypt and give rise to specialized Paneth, enteroendocrine, goblet, and columnar cells 
(43), among many others. 
The presence of cardiac-specific stem cells in the adult mammalian heart remains 
controversial. While lower vertebrates such as teleosts and amphibians are able to regenerate 
large parts of their myocardium throughout adulthood (44), most mammals, including humans, 
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cannot. Until recently it was thought that mammalian cardiomyocytes lose the ability to 
regenerate shortly after birth, but it was discovered that a small portion of these cells can re-enter 
the cell cycle and divide in adulthood (45, 46). Other more recent studies have confirmed that 
cardiomyocyte turnover occurs throughout the life of mammals, but rate estimates are mostly 
low and vary widely. One clever study took advantage of the spike of carbon-14 (14C) levels in 
the atmosphere in the 1950s and 1960s from above ground nuclear testing. The investigators 
used 14C levels to determine the birth date of cardiomyocytes and showed that at age 25, new 
cardiomyocytes form in the human heart at a rate of about 1.5% per year, but this rate drops 
dramatically as we age (47). Another group also measured 14C levels to estimate that the rate of 
cardiomyocyte turnover in adult humans is much higher, between 7-23% per year (48), while 
other groups estimated that the actual value is between 1-2% per year in both adult mice and 
humans using [3H]thymidine (49) and imaging assays (50). The fact that terminally differentiated 
cardiomyocytes can regenerate at all led some to hypothesize that there are resident cardiac stem 
cells in the adult mammalian heart that give rise to the majority of new cardiomyocytes, although 
others argue that these regenerated cells are derived solely from mature cardiomyocytes re-
entering the mitotic cell cycle. Several groups have identified cells that express c-kit as adult 
cardiac progenitors (51, 52), others claim that expression of just SCA can be used to identify 
cardiac stem cells (53), and still others believe that CD31-/SCA1+ side population cells obtained 
from FACS analysis of adult heart tissue are the true cardiac stem cells (54). Whether or not the 
adult human heart actually holds a population of stem cells able to regenerate functional 
cardiomyocytes, it is obvious that the presence of these cells alone is not enough to replenish all 
of the cells that are lost to apoptosis or necrosis during a cardiac event. Isolating these purported 
cardiac stem cells and expanding them in vitro to sufficient numbers for clinical trials has proven 
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difficult, making them impractical as a therapy for mending a wounded heart. Taking this into 
consideration, along with the apparent safety of transplanted adult progenitor cells, there has 
been much focus on using other adult stem cells, primarily those derived from bone marrow, for 
clinical trials of cell-based therapy for the heart. 
1.3.2 Adult stem cells and cardiac ischemia: Clinical trials  
In an early study, bone marrow mononuclear cells (BMMNC) were injected into the area 
bordering the site of MI in mice. Visual tracking of the eGFP-expressing BMMNC led to the 
conclusion that the cells differentiated into functional cardiomyocytes and improved left 
ventricular (LV) function (55). These results were so convincing that very soon after, a similar 
therapy was attempted with autologously derived BMMNC on a 46 year old human male who 
had sustained an acute MI, with a significant improvement in cardiac function (56). However 
subsequent studies employing extensive fate tracking of transplanted cells in mice demonstrated 
that HSC derived from BMMNC do not acquire a cardiac phenotype, suggesting a more cautious 
interpretation. The eGFP+ cardiomyocytes observed in the Orlic study (55) were likely due to 
autofluorescence, which is common in injured cardiac tissue following MI, or fusion of eGFP+ 
BMMNC with endogenous cardiomyocytes (57, 58). Multiple clinical trials have delivered 
BMMNC to almost 2000 patients for cardiac repair, and meta-analyses of the data clearly 
demonstrate that while it is a safe treatment for MI, it is not particularly effective, with only 
modest clinical improvements and no significant improvement in LV function (59-61).  
 Trials with MSC have also had inconsistent but more positive results. Pre-clinical studies 
in large animals (swine) showed that autologously-derived MSC robustly engraft in the infarcted 
heart with modest improvements in cardiac function (62, 63). In phase 1/2 clinical trials, 
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treatment of MI with MSC improved LV function at 3 but not 6 months after MI (64), and 
documented the overall safety of this approach (65). Other clinical trials demonstrated that 
patients injected locally or percutaneously with MSC after MI had global reduction in scarring 
(66, 67). In a clinical trial comparing the efficacy of MSC with BMMNC for treatment of 
ischemic cardiomyopathy, MSC but not BMMNC reduced infarct size and improved regional 
myocardial function (68). In the PROMETHEUS study, six patients with CVD received 
injections of autologous MSC and MRI was used to measure scar size, perfusion, wall thickness, 
and contractility after 0, 3, 6, and 18 months (69). While patients showed reduced scar size, 
contractile improvement, and improved LV function, the results are inconclusive because there 
was no placebo group, but the improvements observed were very promising. Another interesting 
approach taken by Bartunek et al. cultured autologously derived MSC with a cytokine cocktail to 
induce partial cardiogenic differentiation, and delivered these cells by transendocardial injection 
to more than 30 patients with ischemic heart failure (70). LV function was significantly 
improved in the cell therapy group compared to the placebo group, and patients receiving the 
primed MSC experienced overall higher scores on numerous clinical parameters. The safety of 
this approach was also demonstrated by a two year follow-up period with no negative effects 
from MSC transplantation. 
 While the use of bone marrow derived adult stem cells appears to be clinically safe in 
treating cardiac ischemia, the long-term success of this approach is questionable. Some trials 
describe modest improvements in cardiac function while others do not, but the consensus is that 
neither HSC derived BMMNC nor MSC transdifferentiate into cardiomyocytes in vivo. 
Observed clinical improvements in patients receiving these cells are most likely due to indirect 
mechanisms such as delivery of paracrine factors to improve angiogenesis and vascularization, 
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and potentially the mobilization of resident cardiac stem cells or cardiomyocytes to partially 
regenerate damaged cardiac tissue. There is little convincing evidence that adult stem cells can 
actually differentiate into functional cardiomyocytes in vitro (66, 71, 72). Paracrine factors alone 
are unlikely to be sufficient to restore function to extensively scarred myocardium and diseased 
cardiac tissue. As an alternative, because ESC and iPSC (collectively pluripotent stem cells, 
PSC) can differentiate into any cell type, considerable time and effort have been put forth to 
devise ways to utilize these cells to develop safe and effective clinical therapies for ischemic 
cardiac disease.  
1.3.3 Pluripotent stem cells and cardiac therapy 
Embryonic stem cells are derived from the inner cell mass of the blastocyst and are able to grow 
indefinitely in culture and give rise to cells of all of the three germ layers, endoderm, ectoderm, 
and mesoderm (73). Mouse (murine) ESC (mESC) were first derived by Evans and Martin in 
1981 (74, 75) and are the best characterized of the PSC. Human ESC (hESC) were first isolated 
in 1998 (76) and have since been at the center of great scientific interest as well as ethical 
controversy. In 2006, a group in Japan led by Shinya Yamanaka reported that mouse fibroblasts 
could be reprogrammed to adopt a pluripotent state similar to ESC through the introduction by 
retroviral transduction of the genes Oct4, Sox2, c-Myc, and Klf4 (77). These cells, called 
induced pluripotent stem cells (iPSC), are functionally identical to mESC with similar 
morphology, gene expression patterns, capacity for proliferation, and ability to form teratomas. 
Moreover, mouse iPSC are competent for germline transmission, giving rise to adult chimeras 
(78-80). In 2007, the mouse studies were replicated by expressing the same four factors in 
human fibroblasts, successfully enabling for the first time the ability to derive autologous 
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pluripotent stem cells that can be used similarly to hESC without the ethical concerns (81). The 
generation of pluripotent stem cells from somatic cells offers great potential for disease-specific 
model systems, drug discovery, and the production of individualized regenerative therapeutics 
(82). While c-Myc is linked to cardiovascular gene expression (83), strategies to eliminate this 
proto-oncogene from the original reprogramming Yamanaka factors were immediately explored 
in order to reduce the oncogenic potential of the reprogramming approach and make iPSC safer 
for future human therapies. Reprogramming has since been achieved by safer means, without the 
use of c-Myc (84) and through the introduction of the reprogramming factors using non-
integrative technologies (85-88). 
The morphology of PSC is distinct from differentiated cell types. PSC colonies are very 
round with a well-defined border and appear glassy under the microscope. They express high 
levels of alkaline phosphatase (89) and telomerase (90) activity, both of which are 
downregulated in differentiated cell types. A complicated network of transcription factors 
regulates pluripotency in PSC. Oct4, Sox2, and Nanog are key factors at the core of the 
regulatory network that maintains the pluripotency of stem cells (91, 92). Oct4 is a POU family 
transcription factor that is specifically expressed in the ICM of the blastocyst and acts as a 
gatekeeper to prevent stem cell differentiation (93). Oct4 forms heterodimers with Sox2, an 
SRY-related HMG box (Sox) family member, to bind to and regulate a set of downstream targets 
(94), including the respective regulatory regions of their own genes (95). Pluripotency is also 
regulated through complex epigenetic mechanisms such as histone modification, DNA 
demethylation, chromatin remodeling, and microRNAs (reviewed in (96)).  
Because they have been studied extensively for more than three decades, more is known 
about mESC than any other type of PSC. mESC can be maintained in culture in an 
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undifferentiated state with a normal karyotype for long periods of time with relative ease. 
Culturing mESC on a feeder layer of irradiated or mitotically inactivated mouse embryonic 
fibroblasts (MEF) effectively inhibits spontaneous differentiation (74). mESC can be maintained 
in a pluripotent state without feeder cells by using the cytokine leukemia inhibitory factor (LIF) 
in media containing fetal calf serum, which effectively inhibits their differentiation and supports 
proliferation (97). LIF-mediated signaling occurs via heterodimerization of two class I cytokine 
receptors, the low-affinity LIF receptor and gp130 (98), activating the latent transcription factor 
STAT3 by phosphorylation (99). While maintenance of pluripotency through the canonical 
Jak/STAT pathway via LIF requires the inclusion of serum in the mESC media, addition of 
TGFβ superfamily member BMP4 along with LIF can be sufficient to maintain self-renewal in 
the absence of serum through phosphorylation of Smad1 and activation of the Id (inhibitor of 
differentiation) family (100).  
The maintenance of pluripotency of human PSC (both hESC and hiPSC) is regulated 
through different mechanisms than that of mouse PSC. Unlike murine ESC and iPSC, the 
presence of LIF cannot maintain human PSC in a self-renewing state. Human PSC are more 
challenging to culture than their murine counterparts because they are more prone to spontaneous 
differentiation and exhibit poor survival when passaged as single cells upon enzymatic 
dissociation. Experiments using human PSC often produce inconsistent results due to variability 
in media, matrix, and culture conditions (101). They require expensive specialized media 
containing basic fibroblast growth factor (bFGF) (102). Yet like murine PSC, human PSC can be 
cultured nearly indefinitely while retaining their ability for self-renewal and differentiation, and 
are similarly often grown on fibroblast feeder cells. However the addition of BMP4 to the media 
of human PSC induces their differentiation into trophoblast or primitive endoderm-like cells 
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(103). Inhibition of BMP signaling by addition of BMP4 antagonist Noggin can contribute to the 
maintenance of pluripotency of human PSC (104). Because human PSC are more clinically 
relevant than murine PSC, there has been a great deal of effort focused on moving from a culture 
system dependent on serum-rich media and a MEF feeder matrix toward a system using defined 
media (105). Even more recently, chemically defined xeno-free media and matrices have been 
developed for the derivation and culture of human iPSC for potential clinical translation (106, 
107).  
Pluripotent stem cells offer great promise for cell-based treatment of ischemic heart 
disease. Because of their characteristic plasticity and self-renewal, they can proliferate 
indefinitely in culture, enabling them to be grown in large numbers for use in research. In theory, 
PSC are ideal for cell-based therapies because they can differentiate into any cell type in an adult 
organism, enabling them to regenerate any tissue or organ.  
Transplantation of undifferentiated or partially differentiated human and mouse 
embryonic stem cells into animal models of myocardial infarction have produced some 
promising results, including in vivo differentiation of ESC into cardiomyocytes and significant 
improvement in heart function. Tomescot et al. primed hESC with BMP2 and fibroblast growth 
inhibitor SU5402 so that they expressed mesoderm and cardiac genes ISL1, NKX2.5, MEF2C, 
and α-ACTININ. These primed hESC were injected into a rat MI model, and two months after 
transplant, functional human cardiomyocytes were detected in the injected animals (108).  
However the potential for the formation of teratomas, rapidly proliferating tumors containing cell 
types from all three germ layers, remains an important concern in the use of undifferentiated 
embryonic stem cells from mouse or human origin (109, 110). Nelson et al. reported that 
injection of even small numbers of undifferentiated mouse ESCs into an infarcted mouse heart 
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resulted in significant improvement in heart function, including increases in ejection fraction and 
peak mitral blood flow velocity, and showed evidence that some of the transplanted cells 
differentiated into functional cardiomyocytes. Unfortunately more than 20% of the animals 
developed ESC-derived teratomas in the pericardium (111). One way to avoid the issue of 
teratoma formation is to differentiate ESC toward a desired cell type in vitro prior to transplant. 
Both mouse and human PSC can be differentiated into cardiomyocytes in vitro through a variety 
of mechanisms (112-115), though the safest and most efficient ways to accomplish this fate 
specification are still being investigated. While directed differentiation of PSC is an area of 
intense study, no current differentiation protocols can produce 100% of the cell type of interest, 
and lingering pluripotent cells is always a major concern. Removal of undifferentiated cells can 
be achieved through mechanisms described in section 1.3.5. As we begin to understand more 
about fate determination in pluripotent cells, we are discovering ways to use culture conditions, 
cell sorting, and other techniques to manipulate them.  
1.3.4 Cardiac differentiation of murine PSC 
The potential of mouse embryonic stem cells to form spontaneously beating cardiac cells in vitro 
was first reported in 1985 (116), and efforts to understand and control this process have 
continued since. While numerous techniques have been described to produce cardiomyocytes 
from mouse embryonic stem cells, most begin with the aggregation in suspension of ESCs to 
form embryoid bodies, structures containing a mixture of differentiating cells with derivatives 
from the three germ layers which resemble the structure of a mouse embryo (117). To create 
embryoid bodies, mESC are trypsinized and resuspended at a low concentration in media devoid 
of LIF (118). The cells are then aggregated either through the use of plates with low attachment 
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surface coatings, swirling plates, or by creating hanging drops of cells on the tops of bacterial 
petri dishes. After several days, the embryoid bodies can be plated on gelatin coated plates for 
further outgrowth and differentiation, or dissociated and subjected to sorting or various 
treatments. Embryoid bodies allowed to attach and continue to differentiate will typically form 
spontaneously contracting areas indicative of cardiomyocyte formation at a low frequency, 
influenced by a number of factors including cell line and culture conditions (116). The difficulty 
has been unraveling the events that result in cardiomyogenesis and intervening to create a highly 
enriched population of cardiac cells. 
Kouskoff et al. have described an elegant method to generate cardiomyocytes from 
transgenic mouse embryoid bodies. They engineered a line of mESC from mice with the GFP 
gene integrated in the Brachyury locus under the control of the Brachyury promoter (119). 
Brachyury is a member of the T-box family of transcription factors and the earliest marker of the 
mesoderm, the germ layer that gives rise to tissues such as skeletal muscle, bone, blood, and 
heart (120). Using embryoid bodies created from this cell line, they were able to sort for cells of 
mesodermal lineage based on GFP expression. They additionally sorted based on expression of 
vascular endothelial growth factor receptor 2 (VEGFR2, Flk-1). Flk-1 is vital for vascular 
endothelial and hematopoietic differentiation, and is transiently expressed during the formation 
of cardiac tissue (121). Their experiments showed that only the day 3.25 GFP+ (Brachyury+)/Flk-
1- population contained cells with cardiogenic potential. In subsequent experiments, they 
determined that stage-specific expression of Flk-1 in embryoid body differentiation marks pre-
cardiac mesoderm. They found that by sorting and reaggregating GFP+/Flk-1- cells after 3.25 
days of embryoid body differentiation, and resorting at day 4.25, the population that is GFP+/Flk-
1+ is highly enriched for cardiac progenitors (122). They were able to produce a population 
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containing greater than 50% cardiomyocytes as determined by cardiac-specific gene expression, 
a vast improvement over the 1 – 5% that form from unmanipulated embryoid bodies (Figure 5).  
 
 
 
 
 
Figure 5. Sorting strategy to enrich EB cells for cardiac precursors.  
Mouse ESC were differentiated in EB then sorted after 3.25 days based on GFP-Bry and Flk-1 
expression. GFP-Bry+/Flk-1- cells were reaggregated and sorted again on day 4.25. This later emerging 
Flk-1+ population is distinct from the earliest Flk-1+ population and is highly enriched for cardiac 
progenitor cells. (119, 122) 
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These studies highlight the tight temporal control of cardiogenesis, but more recent 
findings by Gordon Keller’s group show that restriction of cardiac potential to this day 4.25 Flk-
1+ population is not absolute (123). These investigators found that only sorted cells with cardiac 
potential express Notch4, and they describe the generation of an ES cell line with tet-inducible 
Notch4 expression. By inducing Notch4 signaling, they were able to respecify the day 3.25 
GFP+/Flk-1+ population to a cardiac fate, generating greater than 60% cardiomyocytes. This 
procedure represents a significant improvement over their previously described method as it 
eliminates one sorting step and provides greater efficiency of cardiomyocyte generation from a 
potentially larger pool of starting material. 
Another strategy that incorporates cell sorting to enrich for cardiac progenitors was 
described by Nelson et al (124). They used systems-expression profiling along with 
bioinformatic network analysis to screen for cell surface proteins expressed at distinct stages of 
embryoid body formation from mESC, and identified the chemokine receptor CXCR4 as highly 
over-represented during cardiac induction (124). After five days of in vitro differentiation as EB 
in hanging drops, sorting for cells co-expressing CXCR4 and Flk-1 produced a population highly 
enriched for cardiac progenitors. Following sorting and reaggregation, further differentiation of 
these cells into spontaneously beating cardiac tissue expressing cardiac transcription factors was 
observed. The advantage of this approach is that it does not require the generation or acquisition 
of a transgenic mESC line, making it more immediately and widely useful to others in the field. 
An alternative approach to sorting for cardiac progenitors from partially differentiated 
embryoid body cells is to use culture conditions, gene transfer, or treatment with small molecules 
to drive pluripotent stem cells toward a cardiac lineage. Perhaps the most straightforward 
approach is to modify the differentiation media to contain growth factors or drugs capable of 
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altering cell signaling and influencing cells to adopt a cardiac fate. Addition of VEGF to 
embryoid body differentiation media has been shown to significantly enhance the differentiation 
of mESC into cardiomyocytes (125). Bone morphogenetic proteins (BMP) are a group of 
secreted signaling proteins that are widely expressed during embryogenesis and development. 
Expression of BMP2 has been shown to be vital at certain stages in cardiogenesis (8), while its 
suppression can enhance cardiac development in a context dependent fashion (126, 127). 
Treatment of mESC with Noggin, a BMP antagonist, for three days prior to the onset of 
differentiation resulted in the formation of large numbers of beating embryoid bodies (126), 
while treatment during the first 24 hours of differentiation with small molecules dorsomorphin 
(128) or DMH1 (129), specific inhibitors of BMP signaling, leads to a significant expansion of 
the cardiomyogenic lineage. 
Since iPSC were first derived in 2006, generating cardiomyocytes from iPSC for patient-
specific regenerative cardiac therapy has been a major focus. Because they are nearly identical to 
mESC, murine iPSC are differentiated into cardiomyocytes in vitro utilizing many of the same 
techniques. Mauritz et al. described the cardiac differentiation of murine iPSC generated through 
retroviral transduction with Oct4, Sox2, Klf4, and c-Myc. They compared the efficiency, gene 
expression, and functional characteristics of cardiomyocytes created from spontaneously 
differentiating EB cells between mESC and iPSC. While the cardiac differentiation of iPSC was 
less efficient than mESC, the derived cardiomyocytes were functionally identical (130).  
Murine iPSC generated without c-Myc were differentiated via EB formation in hanging 
drops. Cardiomyocytes were isolated from the EB using Percoll gradient centrifugation and 
characterized. Murine iPSC-derived cardiomyocytes performed similarly to those derived from 
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mESC in kinetic and gene expression assays, and these iPS progeny cells were detected with 
successful engraftment and functional contribution in the hearts of healthy chimeric mice (131). 
Exogenous expression of genes known to be involved in cardiogenesis can be a powerful 
tool to influence the fate of PSC. Techniques such as infection with recombinant viral vectors 
and transfection can be used to deliver genes to PSC at specific times before and during 
differentiation. Craft et al. described the use of the replication defective HSV vector, JDββHE, to 
infect mESC and embryoid body cells and deliver the myogenic transcription factors Pax3 and 
MyoD (132). They used microarray analysis to determine that infection with these vectors 
augmented expression of genes involved in muscle lineage determination, demonstrating that 
gene transfer from an HSV vector has the potential to alter the fate of differentiating pluripotent 
cells. 
GATA4, NKX2.5, and TBX5 are cardiac-specific transcription factors co-expressed in 
the precardiac mesoderm, and are among the earliest and most vital factors active during cardiac 
induction (133). Together with myocardin (MYOCD), they are considered to be the master 
regulators of heart development (134). Experimental disruption of GATA4, NKX2.5, or TBX5 
leads to failure of normal heart development and cardiomyocyte maintenance, and embryonic 
death in mice (135-140). GATA4 and NKX2.5 are concurrently expressed and have been shown 
to physically interact in vitro and in vivo to synergistically transactivate expression of genes 
involved in cardiac differentiation, including atrial natriuretic factor, alpha myosin heavy chain 
(α-MHC), and cardiac troponin T (cTnT) (141). Yamada et al. have used retroviral transduction 
of mesenchymal stem cells with GATA4 and NKX2.5 to produce a population of cells with 
cardiomyocyte properties and expression profiles (142). Recently, strides have been made in 
completely bypassing a pluripotent intermediate by transdifferenting fibroblasts and other 
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somatic cells directly into cardiomyocytes (induced cardiomyocytes, iCM) with several different 
combinations of cardiac transcription factors. Ieda et al. used a combination of GATA4, TBX5, 
and MEF2C (GTM) to directly reprogram cardiac and dermal fibroblasts into cardiomyocytes in 
vitro (143). Qian et al. used the same GTM combination to transdifferentiate cardiac fibroblasts 
in vivo into cardiomyocytes (144). Also in 2012, Song et al. included HAND2 into the GMT 
mixture to achieve more efficient transdifferentiation of adult mouse tail-tip fibroblasts in vitro 
and cardiac fibroblasts in vivo, and reported moderate improvements in cardiac function 
following surgically induced MI (145). However other reports (146) have failed to repeat the 
success of these initial experiments, leaving a lot of questions unanswered. Is the activation of a 
cardiac reporter gene (eg. α-MHC promoter driving eGFP expression as in (143)) sufficient to 
conclude that transdifferentiation into true cardiomyocytes was achieved? There are a number of 
criteria used (147), but there is currently no clear consensus about the characteristics required for 
a cell to be considered an iCM. Still this is an exciting area of research for cardiac regenerative 
medicine because the lack of a PSC intermediate removes the risk of teratoma formation in 
patients transplanted with iCM. 
1.3.5 PSC-derived cardiomyocytes for cardiac regeneration 
Most of the recent pre-clinical studies with PSC for cardiac regenerative therapy have focused on 
utilizing human PSC in vitro-derived cardiomyocytes to treat animal models of MI. Because of 
the risk of teratoma formation in recipients of PSC-derived cell types, they have not yet been 
used in clinical trials in humans.  
It is physiologically more meaningful to use mouse PSC and their derivatives for cell-
based therapy in mouse models due to the small size of mice and their faster heart rate compared 
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to larger mammals. Human cardiomyocytes may survive and electrically couple in rodent hearts, 
but they cause arrhythmias and are not necessarily the best model for human CVD therapy. 
However because the ultimate goal is to regenerate the human heart, animal models including 
mice, rats, guinea pigs, monkeys, sheep, and pigs have been implanted with hESC-derived 
cardiomyocytes with generally favorable results. A 2009 preclinical study by Menard et al. did 
use cardiac committed mESC in a sheep model of MI. Mouse ESC were cultured for 36 hours 
with BMP2 prior to transplantation, and these cells were able to engraft and fully differentiate 
into cardiomyocytes, significantly increasing LV ejection fraction (LVEF), the amount of blood 
pumped from the LV with each heartbeat, a typical measure of cardiac functionality (148). 
Human ESC-derived cardiomyocytes were transplanted into rat (149) and pig (150) models of 
MI and found to interact normally with endogenous cardiomyocytes to form new myocardium. 
They expressed cardiomyocyte genes α-MHC, MLC-2v, and ANF, and the graft sizes increased 
over time indicating that the implanted cells proliferated in vivo. Electrophysiological mapping 
and histopathological examination were used by Kehat et al. and Xue et al. to demonstrate that 
hESC-derived cardiomyocytes can form pacemaker cells and electrically couple to the host 
myocardium in pigs (150) and guinea pigs (151). A number of other studies showed improved 
function of the post-MI heart upon implantation of hESC-derived cardiomyocytes into animal 
models including mouse (152), rat (153), and monkey (154) models. Human iPSC-derived 
cardiomyocytes have been used similarly in pre-clinical studies with largely positive results. For 
a comprehensive review of these experiments, see Lalit et al. (155).  
All of this data taken together hints at the promise of PSC-derived cells for cardiac 
regenerative therapy, but there is still much to be learned before it can be translated to the clinic. 
Most importantly, we must develop methods to ensure that any remaining undifferentiated cells 
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are completely removed from the culture to remove the risk of teratoma formation in patients. 
This can be accomplished in a number of ways, including using antibodies against stem cell-
specific surface antigens such as SSEA-5 (156) and certain lectins (157) to deplete 
undifferentiated cells. Other questions remain, such as what is the ideal cell type for transplant 
into the injured heart? Would a more or less committed cell type survive and function 
effectively, or is a mixture of cell types that provide mutual support for growth and 
vascularization a better choice since the heart itself is made of several different types of cells? 
How can enough cells be safely and efficiently produced to meet the overwhelming demand? 
When is the optimal time to treat patients with cell-based therapies following a cardiac event, 
and how should the cells be delivered?  
The answer to the latter has been the subject of much research in recent years. In most 
pre-clinical studies, cells have been injected directly into the myocardium along the site of scar 
formed from infarction. While the cells do engraft and function, the survival of the donor cells is 
often poor. Strategies to improve graft survival and the outcome for the host, such as the use of 
PSC-based biomimetic materials (158), cardiopatches (159), and other mechanisms, are currently 
being investigated. 
1.4 HERPES SIMPLEX VIRUS TYPE 1 (HSV-1) 
1.4.1 HSV-1 genome structure 
Herpes simplex virus type 1 (HSV-1) is a double stranded DNA virus with a broad host cell 
range. It is well suited for use as a gene delivery vector for PSC due to its ability to infect many 
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cell types, including PSC and their derivatives (132). Unlike retroviruses, HSV-1 remains 
episomal so that genomes are lost over time as host cells divide, and host chromosomes are not 
disrupted by integration of the viral genome. HSV-1 has a large ~152 kb genome that encodes 
over 80 proteins. Approximately half of these are not essential for viral replication in cell culture, 
and deletion of their genes through genetic recombination makes it possible to insert large and 
multiple transgenes. The HSV genome is segmented into unique long (UL) and unique short (US) 
sequences connected by inverted repeat elements called the joint.  
1.4.2 HSV-1 gene expression cascade 
HSV-1 initiates a temporal cascade of gene expression following infection and entry into a host 
cell, involving the sequential expression of immediate early (α), early (β), and late (γ) genes 
(160). Five immediate early genes are expressed upon viral genome entry into the host cell 
nucleus, infected cell protein (ICP) 0, ICP4, ICP22, ICP27, and ICP47. The promoters of the 
immediate early genes contain an enhancer element that is responsive to VP16, an HSV 
structural protein that is transported into the nucleus along with the viral DNA (161). The 
primary function of the immediate early genes, particularly ICP4, is to activate expression of the 
early genes that encode viral proteins necessary for DNA replication. Late genes are transcribed 
following DNA replication and primarily encode virion structural proteins (160). Of the five 
immediate early genes, only ICP4 and ICP27 are absolutely required for expression of early and 
late genes and DNA synthesis (162). ICP4 serves as a transactivator of viral genes, while ICP27 
is vital for processing and transport of viral mRNAs. ICP0 and ICP22 are not required for HSV 
replication in vitro, but also play a role in the transactivation of viral genes and improve gene 
expression and replication efficiency of the virus (163).  
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1.4.3 Replication defective HSV-1 vectors 
The rigid sequence of HSV gene expression makes generation of replication defective mutants 
for use as vectors relatively straightforward. By eliminating one or more immediate early genes 
required for activation of the gene expression cascade, the virus cannot express early or late 
genes, replicate its DNA, or produce infectious progeny. Replication and production of these 
defective vectors can be achieved through the use of a complementing cell line that provides the 
missing gene functions in trans (164). However simply eliminating the replication competence of 
HSV does not make it a suitable vector. Even in the absence of lytic viral replication, ICP0, 
ICP4, ICP22, and ICP27 are toxic to cells (165). Elimination of ICP0 enhances the survival of 
infected cells (166), but also drastically reduces transgene expression (167) as well as early and 
late viral gene expression (168). Achieving a balance between toxicity and robust transgene 
expression is vital in the design and construction of replication defective HSV vectors. With this 
in mind, vectors JDββHE (132) and JΔNI8GFP (169) were developed in our lab.  
1.4.4 HSV-1 vector JDββHE 
Vector JDββHE (132) contains deletions of two immediate early genes, ICP4 and ICP22, as well 
as the internal repeated sequences (JD, joint deleted). Immediate early genes ICP0 and ICP27 
were placed under the control of the promoter of β gene thymidine kinase and are expressed with 
early gene kinetics. This genome design results in a vector that can replicate only in the presence 
of ICP4, which is supplied in trans by the Vero cell line derivatives 4BLA or 7b in response to 
infection with HSV. The 4BLA cell line expresses ICP4 under the control of the ICP4 promoter 
(132), and the 7b cell line in addition expresses ICP27 under the control of the ICP27 promoter 
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(170). JDββHE also contains a copy of the ICP0 promoter driving expression of lacZ in the UL41 
locus, disrupting the virion host shutoff function that shuts down host protein synthesis (171) and 
allowing expression of lacZ to monitor transgene expression. JDββHE in addition was 
engineered to express GFP under the control of the HCMV IE promoter in the deleted ICP4 
locus so that infected cells can be easily visualized by fluorescence microscopy. These 
modifications together provided a vector with abundant room for insertion of foreign sequences 
and low toxicity to host cells. RNA analyses have shown that expression of the ICP0 gene is up 
to 100-fold lower in JDββHE-infected cells than in cells infected with an ICP0+ reference virus 
(132). This low level of ICP0 gene expression provides enough ICP0 function to allow complete 
transduction in an MOI-dependent manner and robust transgene expression in both embryonic 
stem cells and embryoid body cells, but minimizes ICP0-mediated toxicity. Infection of 
embryonic stem cells with JDββHE does not interfere with self-renewal or mesoderm formation, 
as evidenced by normal expression of early mesoderm markers Brachyury and Flk-1 in embryoid 
bodies derived from embryonic stem cells infected at MOIs of up to 100 (132). 
1.4.5 HSV-1 vector JΔNI8GFP 
The design of vector JΔNI8GFP was conceived to improve upon JDββHE by eliminating all 
residual ICP0- and ICP27-mediated toxicity without abolishing robust transgene expression in 
dividing and non-dividing cells. All manipulations to engineer JΔNI8GFP were carried out in 
bacteria utilizing an HSV-bacterial artificial chromosome (BAC) as described in detail for a very 
similar vector, JΔNI7GFP, by Miyagawa et al. (169). JΔNI8GFP differs from JΔNI7GFP (169) 
only by the additional deletion of UL41, making it more similar to JDββHE.  
Deletion of ICP0 expression leads to global silencing of the viral genome in infected host 
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cells, resulting in a complete loss of transgene expression (172). However, it was found that 
transgene(s) placed within the latency-associated transcript (LAT) locus were selectively 
protected from epigenetic silencing, resulting in robust expression even in the absence of any 
immediate early gene expression (169). Latency is a quiescent state in which expression of viral 
lytic genes has been extinguished. However, during latency, HSV persistently expresses a 
latency-associated non-coding RNA (LAT). The presence of LAT RNA, a stable 2 kb intron 
spliced from an 8.3 kb LAT mRNA, is the hallmark of latency. Elements of the latency promoter 
have been shown to promote gene expression from HSV vectors. LAT expression during latency 
is controlled by latency associated promoters (LAP) 1 and 2 (173, 174). LAP2 can act as a long-
term enhancer element for transgene expression. A region known as LATP2 contains the LAP2 
element and extends further into the 2 kb intron region (175). The LAT locus is also protected 
from viral genome silencing during latency by regions rich in CTCF binding sites called CTRLs, 
with CTRL1 located upstream of LAP1 and CTRL2 in the intron just downstream of LATP2 
(176). 
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2.0  RATIONALE AND SIGNIFICANCE 
2.1 SIGNIFICANCE 
Cardiovascular disease remains a leading cause of death in developed countries, killing 
one in five Americans and adversely affecting the health of at least one in three (177). Advances 
have been made in the treatment of ischemic heart disease, including the use of drugs such as 
angiotensin-converting enzyme (ACE) inhibitors and β-adrenergic blockers to improve cardiac 
function (178, 179). Currently available treatments can improve the prognosis and quality of life 
for patients suffering from heart disease, but they lack the ability to replace cardiac tissue lost to 
the disease. The only established method to cure a patient whose heart has been injured by 
myocardial infarction or damaged by other diseases is heart transplantation, an option that is only 
rarely available.  
2.2 CELL-BASED THERAPY FOR CARDIAC DISEASES 
Cell-based therapy for the treatment of cardiac diseases has the potential to replace lost 
cardiomyocytes and therefore has become an area of intense study. While many laboratories 
have published encouraging results of transplantation of different cell types into animal models 
of myocardial infarction, the type of cells transplanted is a key factor in the ultimate success of 
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this approach. Transplantation of fully committed cells into animal models of infarcted hearts has 
had mixed results, and these cells are of limited availability and not practical for clinical use. 
Adult progenitor cells can be autologously derived and studies have shown moderately improved 
outcomes in patients receiving these cells, but they do not differentiate in vivo into 
cardiomyocytes. Any improvements observed upon adult stem cell therapy in the heart are due to 
paracrine effects or increased vascularization in the damaged area, neither of which is sufficient 
to replace lost cardiac function. Pluripotent stem cells (ESC and iPSC) can differentiate into 
functional cardiomyocytes, but teratoma formation in the host is an important hurdle that must be 
overcome before PSC or their derivatives can be transplanted into patients.  
Much effort is currently devoted to determining the best procedures to achieve in vitro 
differentiation of PSC into cardiomyocytes. Induced expression of one or more genes vital to 
cardiac programming of PSC is a logical strategy to influence PSC differentiation, but until 
recently, gene transfer methods for PSC have been limited by inefficiency, vector toxicity, and 
concerns regarding vector integration into the host-cell genome.  
2.3 REPLICATION DEFECTIVE HSV VECTORS FOR PLURIPOTENT STEM 
CELLS 
Replication defective HSV vector JDββHE was designed to be non-toxic, yet capable of efficient 
transgene delivery to and expression in pluripotent stem cells and their derivatives without 
compromising the cell’s ability to self-renew and differentiate along the mesodermal lineage. 
Experiments involving infection of mESCs with JDββHE and subsequent formation of embryoid 
bodies have demonstrated that the vector does not have a significant effect on the expression of 
 34 
the mesoderm marker Brachyury or the hemangioblast marker Flk-1. JDββHE-based vectors 
containing the myogenic genes Pax3 and MyoD have been shown to alter gene expression 
profiles of embryoid body cells such that target genes relevant to muscle development were 
upregulated, indicating that genes expressed from this vector have the potential to influence 
lineage determination in pluripotent stem cells (132). We engineered the JDββHE vector, as well 
as a similar but yet further crippled vector, JΔNI8, to deliver vital early cardiac transcription 
factors to mESC. Initially JDββHE-based vectors seemed ideal, but when the new JΔNI8-based 
vectors were tested, it became clear that they were better suited for our purposes because of their 
reduced toxicity and strong expression of transgenes from the protected LAT locus. Both vector 
types expressing cardiogenic transgenes were used to enhance cardiac differentiation of mESC 
signified by increased upregulation of genes involved in cardiomyogenesis (Table 1) as 
measured by qRT-PCR, and by increases in spontaneously contracting cardiomyocytes in EB 
cultures derived from experimental compared to control vector-transduced mESC.  
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Table 1. Genes involved in cardiac differentiation used for qRT-PCR experiments 
 
 
 
 
 
 
References: Foxa2 (180, 181), Gata6 (181-184), Tbx20 (185-187), Myocd (140, 188), Sox17 (181, 189), 
Mlc2a (190), Myo5b (181, 191), cTnI/cTnT (192). 
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3.0  CONSTITUTIVE EXPRESSION OF GATA4 IN D3 EMBRYONIC STEM CELLS  
3.1 INTRODUCTION 
The temporospatial expression pattern of transcription factors plays a vital role in cell lineage 
determination in a developing embryo. Commitment of a subset of embryonic cells to adopt a 
cardiac fate is one of the earliest events to occur in embryogenesis, and GATA4 is a key 
regulator of cardiogenesis that is expressed from the earliest stages of cardiac commitment, 
through development, and into adulthood (14). GATA4 is considered to be the master 
transcriptional regulator of cardiac development, and loss of GATA4 function is incompatible 
with life (13). 
GATA4 is a zinc finger transcription factor that binds to the promoters of many cardiac-
specific genes to switch on their expression and drive the ordered proliferation, migration, and 
differentiation of cells in the precardiac mesoderm to form the embryonic heart. GATA4 has a C-
terminal zinc finger to facilitate DNA binding at (a/t)GATAA(g) residues, and an N-terminal 
zinc finger that stabilizes protein-DNA interactions and participates in specific protein-protein 
interactions (193). The GATA4 sequence is highly conserved among mammals, underscoring its 
essential role in the development and function of the heart. 
Cardiovascular disease is the leading cause of morbidity and mortality across the globe. 
The adult mammalian heart lacks significant regenerative capacity, and currently no therapies 
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exist to replace damaged heart tissue. Cell-based treatment for cardiac ischemia offers great 
promise, but much needs to be learned before it can become clinically relevant. Pluripotent stem 
cells are theoretically ideal for cell-based therapies because they can differentiate into any cell 
type in an adult organism, enabling them to regenerate any tissue or organ. However 
transplantation of undifferentiated pluripotent stem cells carries the potential for the formation of 
teratomas, rapidly proliferating tumors containing cell types from all three germ layers (109).  It 
should be possible to avoid the issue of teratoma formation by differentiating stem cells into a 
desired lineage in vitro prior to transplantation. Directed differentiation of pluripotent stem cells 
is an area of intense study as a deeper understanding of fate determination and ways to intervene 
to produce specific cell types are revealed. 
We are interested in using expression of essential cardiac transcription factors to 
influence embryonic stem cell fate and enhance their differentiation into cardiomyocytes. 
Because GATA4 sits atop the hierarchy of the cardiac gene transcriptional network, it is a logical 
target for cardiomyocyte differentiation. In this study, we describe the creation of D3 mESC 
lines that constitutively express GATA4. By using nucleofection and selection with puromycin, 
we generated lines that constitutively expressed varying levels of GATA4. These GATA4-
expressing mESC lines displayed significantly greater cardiogenic potential than their eGFP-
expressing counterpart. One line produced 80% more contracting embryoid bodies than the 
control eGFP-expressing line. Constitutive GATA4 expression in differentiating EB also 
dramatically enhanced the expression of other cardiac genes, including endogenous Gata4, 
Nkx2.5, cardiac troponin I (cTnI), and Mlc2a. 
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3.2 MATERIALS AND METHODS 
3.2.1 Cells and culture conditions 
D3 mouse embryonic stem cells (a gift from T.E. Smithgall, University of Pittsburgh) were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM, Corning) supplemented with 15% 
fetal bovine serum (FBS, GIBCO), 1% non-essential amino acids (GIBCO), 1 mM sodium 
pyruvate (GIBCO), 100 U/ml penicillin (Cellgro), 100 μg/ml streptomycin (Cellgro), 0.1 mM 2-
mercaptoethanol (GIBCO), and 1000 U/ml mouse leukemia inhibitory factor (LIF, Millipore) on 
10 centimeter dishes coated with 0.2% gelatin (Sigma). Media was exchanged daily and cells 
were passaged with trypsin every 2-3 days to maintain a state of self-renewal and minimize 
spontaneous differentiation. 
3.2.2 Construction of GATA4 expression cassette 
A cassette containing the CAG promoter, GATA4 coding sequence, and SV40 polyadenylation 
signal was constructed as follows. Plasmid pCDH (System Biosciences) was modified to replace 
the CMV promoter with the CAG promoter and then human GATA4 cDNA (Open Biosystems) 
was ligated into the plasmid. The CAG promoter was derived from plasmid pPEP100 (kindly 
provided by P. Spear, Northwestern University) (194) as a 1.7 kb SpeI to EcoRI fragment and 
cloned between the SpeI and EcoRI sites of plasmid pCDH as a SpeI to produce plasmid pCDH-
CAG. The 1.4 kb fragment containing the human GATA4 cDNA in pTopo-GATA4 (Open 
Biosystems) was excised using EcoRI and cloned into the EcoRI site of pCDH-CAG to create 
CAGp-GATA4-SV40pA-EF1p-PuroR. The correct orientation of the GATA4 fragment was 
 39 
verified with diagnostic digests. Plasmid CAGp-eGFP-SV40pA-EF1p-PuroR was created as a 
control, and both plasmids were linearized with SpeI prior to Nucleofection.  
3.2.3 Generation of D3 mES cell lines expressing GATA4 and eGFP 
Linearized plasmids CAGp-GATA4-SV40pA-EF1p-PuroR and CAGp-eGFP-SV40pA-EF1p-
PuroR were introduced into D3 mESC via nucleofection. First the plasmids were linearized by 
digestion with SpeI and the DNA was purified from an agarose gel. D3 mES cells were fed four 
hours prior to nucleofection. Cells were prepared for nucleofection by detaching them with 
trypsin, pelleting the cells and washing them with PBS, and resuspension in 90 μl Ingenio 
Electroporation Solution (Mirus). 10 μg linearized DNA was diluted into 10 μl Ingenio 
Electroporation Solution, and mixed with the cells in an electroporation cuvette. The DNA was 
nucleofected into the cells using an Amaxa Nucleofector I set on program A-13. Immediately 
after nucleofection, 500 μl warm media was added to the cells in the cuvette, and the cells were 
plated in gelatin coated 10 cm dishes containing warm ES media with LIF.  Media was changed 
24 h after plating. 48 h after nucleofection, 2 μg/ml puromycin was added to the media for 
selection. Resistant colonies began to appear 24 h after the onset of selection, and were picked 
from 10 cm dishes under a microscope in a hood one week after nucleofection. Each colony was 
placed in one well of a 24 well plate for expansion. At least ten clones were expanded for each 
cell line. Cell lines were characterized by observation of eGFP expression (D3-eGPF), Western 
blotting (D3-GATA4), EB assay, and reverse transcriptase (RT) quantitative real time (q) 
polymerase chain reaction (PCR). 
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3.2.4 Western blot analysis 
Cell lysates were collected from undifferentiated D3-eGFP and D3-GATA4 mESC lines as well 
as from d12 EB in RIPA lysis buffer supplemented with protease inhibitors (Roche). Proteins 
were separated on a 10% polyacrylamide gel and transferred by semi-dry transfer onto PVDF 
membranes. The membranes were washed in Tris-buffered saline (TBS) and blocked for 1 h at 
room temperature in TBS-T (20 mM Tris, 0.5 M NaCl [pH 7.5] plus 0.5% Tween 20) 
supplemented with 10% nonfat dry milk. Primary antibodies were diluted in blocking buffer. 
Diluted antibody was reacted with the blocked PVDF overnight at 4°C, washed 3 times for 10 
min each in TBS-T, and reacted with horseradish peroxidase-conjugated secondary antibody 
diluted in blocking buffer for 1 h at room temperature. The bound Igs were revealed by enhanced 
chemiluminescence (Thermo Scientific). Antibody information can be found in Table 2. 
 
Table 2. Primary and secondary antibodies used for Western blotting 
 
 
Antibody Vendor Cat. Number Dilution 
Primary       
GATA4 Santa Cruz sc-25310 1:100 
GATA4 abcam ab84593 1:100 
Nkx2.5 Santa Cruz sc-81973 1:200 
Nkx2.5 abcam ab91196 1:500 
TBX5 Santa Cruz sc-17866 1:200 
MEF2C Santa Cruz sc-13268 1:200 
2A peptide Millipore ABS31 1:1000 
Secondary       
anti-mouse HRP Sigma RABHRP2 1:10000 
anti-rabbit HRP Sigma RABHRP1 1:2000 
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3.2.5 Embryoid body assay 
Cells were suspended in mESC media without LIF at a concentration of 4x104 cells/ml. 20 μl 
drops of cells were pipetted onto the lid of a petri dish, and the lid was inverted over the dish that 
contained 30 ml sterile water to prevent the drops from evaporating. The cells were incubated at 
37°C with 5% CO2 and allowed to aggregate to form embryoid bodies (EB) and differentiate for 
two days in hanging drops. After 48 h in hanging drops, the EB were pipetted one per well into 
48 well plates, each well containing 500 μl mESC media without LIF. The EB were observed 
daily for the appearance of spontaneously contracting cells, and the number of wells containing 
these cells was recorded each day. 
3.2.6 RNA extraction and qRT-PCR analysis 
Total RNA was extracted from D3 mES cell lines and embryoid bodies using Qiagen RNeasy 
Plus mini kit with gDNA eliminator columns (Qiagen). Reverse transcription was performed on 
1-2 μg RNA in 20 μl final volume using random decamers as first strand primers with Ambion’s 
RETROscript Kit (Ambion), and the resulting cDNA was diluted 1:10 for qPCR analysis. 
Primers were obtained from Invitrogen. Primer sequences and references for qPCR are 
listed in Table 3. qPCR was performed using LightCycler SYBRgreen Master Mix (Roche) and a 
Step One Plus Real-Time PCR System (Applied Biosystems). Cycling conditions were 95°C for 
10 min followed by 40 cycles of 95°C for 15 sec and then 60°C for 1 min. Each cDNA was 
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analyzed in triplicate, and the results for the three wells were averaged. Threshold cycle (Ct) 
values were used to calculate changes in gene expression using the 2-ΔΔCt method (195). 
Expression levels were normalized to HPRT and mRNA expressed relative to uninfected D3 
mESC. 
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Table 3. Primer sequences used for qRT-PCR 
 
 
Gene Forward Primer Reverse Primer 
Product 
Length 
(bp) Reference 
GATA4 (human)                         TTCCAGCAACTCCAGCAACG GCTGCTGTGCCCGTAGTGAG 97 Zhu et al. (196) 
Gata4 GCCCAAGAACCTGAATAAAT CGGACACAGTACTGAATGTCT 195 So et al. (197) 
NKX2.5 (human)                         CTTCAAGCCAGAGGCCTACG CCGCCTCTGTCTTCTCCAGC 210 Zhu et al. (196) 
Nkx2.5 CAGTGGAGCTGGACAAAGCC TAGCGACGGTTCTGGAACCA 217 Lakshmipathy et al. (198) 
Mlc2a                TCAGCTGCATTGACCAGAAC AAGACGGTGAAGTTGATGGG 148 Yamashita et al. (199) 
cTnI                               ACGTGGAAGCAAAAGTCACC CCTTCTTCACCTGCTTGAGG 189 So et al. (197) 
anf                     CTGTTTAAAGATTCTGCTCACC GAGAGACCAGTGAAGAACTAGC 151 So et al. (197) 
HPRT GCTGGTGAAAAGGACCTCT CACAGGACTAGAACACCTGC 249 Anton et al. (200) 
Oct4 TGTTCCCGTCACTGCTCTGG TTGCCTTGGCTCACAGCATC 82 Greber et al. (201) 
Foxa2 CCCTACGCCAACATGAACTCG GTTCTGCCGGTAGAAAGGGA 222 Oda et al. (181) 
Gata6 GCAATGCATGCGGTCTCTAC CATATAGAGCCCGCAAGCAT 185 Oda et al. (181) 
Sox17 CTCGGGGATGTAAAGGTGAA CTTAGCTCTGCGTTGTGCAG 182 Primer3 (202) 
Myo5b ACACTATGTCCGGTGCATCA CCGGTTGAAGAAGTCATGGT 163 Primer3 (202) 
 
 
 
3.3 RESULTS 
3.3.1 mESC lines constitutively expressing GATA4 and eGFP  
In order to determine whether expression of GATA4 increases the cardiogenic potential of D3 
mESCs, cell lines were created to constitutively express human GATA4. An eGFP-expressing 
mESC line was similarly generated for use as an experimental control. Dual gene expression 
 44 
cassettes were constructed with the CAG promoter driving expression of either human GATA4 or 
eGFP and the EF1α promoter driving expression of the puromycin resistance gene (Figure 6A). 
Following linearization, the plasmids were introduced into D3 mESCs by nucleofection and 
transduced colonies were identified by selection for resistance to puromycin. Several individual 
colonies were isolated and expanded. 
mESC expressing eGFP were readily identified by fluorescence microscopy. D3-eGFP 
clonal lines retained normal stem cell morphology and every colony formed by these cells 
robustly expressed eGFP (Figure 6B). Cell lysates were collected from three D3G4 lines (A, B, 
and C), and equal amounts of protein from each line were separated by gel electrophoresis. 
Western blotting demonstrated that the three lines varied widely in their expression of GATA4 
protein (Figure 6C). D3G4-B expressed a high level of GATA4, D3G4-C appeared to express no 
GATA4, and D3G4-A expressed an intermediate level of the protein. No GATA4 expression 
was observed in unmodified D3 mESC or D3-eGFP (data not shown). 
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Figure 6. D3 mESC cell lines for constitutive expression of eGFP or GATA4 
(A) Schematics of the DNA fragments used for nucleofection of mESC to generate eGFP- and GATA4- 
expressing cell lines. (B) eGFP expression in undifferentiated cells from an mESC-eGFP clone at low 
(upper panels) and high (lower panels) magnification. Cells are shown from left to right in brightfield, 
fluorescence, and overlay. (C) Western blot showing expression of GATA4 in three mESC-GATA4 
clonal cell lines. 
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3.3.2 Constitutive GATA4 expression enhances cardiac differentiation in EB 
To determine whether constitutive expression of GATA4 affects mESC differentiation, EB were 
generated from unmodified D3 mESC, D3-eGFP, and D3G4 lines B and C by the hanging drop 
procedure and then plated one per well in 48 well plates. The EB were monitored daily from 
days 8 – 14 after the onset of differentiation for the appearance of spontaneously contracting 
cells, indicative of the presence of mature cardiomyocytes. While unmodified mESC and D3-
eGFP exhibited very low levels of cardiac differentiation, the two D3G4 lines produced many 
more EB with large areas of contracting cells (Figure 7). D3G4-B, the line that expressed the 
highest level of GATA4 protein, had the largest percentage of EB with contracting cells (>90% 
on day 12). Although it appeared from the Western blot of Figure 6C that D3G4-C expressed 
little or no GATA4 protein, these cells also demonstrated dramatically more cardiogenic 
potential than the unmodified mESC or the D3-eGFP line. Almost 65% of D3G4-C EB 
contained visible cardiomyocytes on day 14 compared to a maximum of 17% of control EB.  
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Figure 7. Cardiomyocyte differentiation of modified mESC lines 
Control mESC, D3-eGFP, and D3G4 lines B and C were differentiated in EB. EB with visible contracting 
patches of cells were counted daily from 8 – 14 d after the onset of differentiation. 
 
 
 
3.3.3 Differentiating D3G4 mESCs express higher levels of cardiac-specific genes than 
control D3-eGFP cells 
We examined the expression of selected cardiac genes in late-stage EB derived from D3-eGFP 
and D3G4-B. RNA was extracted on day 12, the day when EB display the greatest 
cardiomyocyte activity as determined in Figure 7. In this experiment, 74% of D3G4-B EB 
contained contracting foci on day 12 while none of the D3-eGFP EB did (Figure 8A). qRT-PCR 
with SYBR Green reagents was used to quantify relative cardiac-specific gene expression as well 
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as expression of Oct4, a pluripotency marker. We examined expression of Nkx2.5, a gene 
expressed in some of the earliest cardiac progenitors through fully differentiated cardiomyocytes, 
as well as cTnI and Mlc2a, genes expressed only in more committed cardiac cell types (see Table 
1). Mouse heart cDNA was included as a positive control for cardiac genes. Gene expression was 
normalized to HPRT cDNA and expressed relative to undifferentiated, unmodified mESC 
(Figure 8B). As expected, Oct4 expression was dramatically downregulated in 12 day old EB 
and was undetectable in mouse heart cDNA. Species-specific primers were used to distinguish 
GATA4 expression from the human transgene and the endogenous murine gene. Although the 
human GATA4-specific primers showed some background amplification with D3-eGFP EB and 
mouse heart cDNAs, the signal from D3G4-B cDNA was more than 100-fold higher. Expression 
of the mouse Gata4 gene, as well as the Nkx2.5 and cTnI genes, was up to ~10-fold higher in 
D3G4-B EB than in D3-eGFP EB. D3G4-B EB also contained over 500-fold more Mlc2a 
mRNA than D3-eGFP EB. Overall, the expression levels of these genes in D3G4 EB more 
closely resembled those in mouse heart than in D3-eGFP EB (Figure 8C). 
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Figure 8. Comparison of gene expression in d12 EB made from D3-eGFP and D3G4-B by qRT-
PCR 
(A) mESC were differentiated for 12 d in EB. RNA was extracted and reverse transcribed. (B) qRT-PCR 
data for Oct4 and cardiac-specific gene expression. Ø, unmodified undifferentiated mESC. Gene 
expression data was normalized to HPRT cDNA and expressed relative to unmodified undifferentiated 
mESC. (C) PCR products from reactions using cardiac gene-specific primers on cDNA from d 12 D3-
eGFP EB, d 12 D3G4-B EB, and mouse heart run on an agarose gel for comparison of cardiac gene 
expression patterns. 
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3.4 DISCUSSION 
The goal of this study was to determine whether continuous expression of high levels of GATA4 
throughout differentiation in EB would increase the cardiogenic potential of mESC. We describe 
the creation of D3 mouse embryonic stem cell lines that constitutively express the early cardiac 
transcription factor (human) GATA4 or eGFP as a control. Differences in cardiogenic potential 
between the experimental and control lines were determined by recording the appearance of 
spontaneously contracting cardiomyocytes in EB cultured for two weeks following the onset of 
differentiation. In addition, we examined the expression of several cardiac-specific genes in 12 
day old EB derived from the highest GATA4-expressing line compared to the eGFP control line.  
Although all lines were maintained under puromycin selection, GATA4 protein levels in 
the three D3G4 lines described here varied widely. GATA4 protein was not detected in D3G4-C, 
while D3G4-B produced robust amounts of the protein and D3G4-A showed an intermediate 
level. Constitutive expression of ectopic GATA4 in differentiating EB from D3G4-B appeared to 
significantly increase the cardiogenic potential of these cells as greater than 90% of these EB 
contained large areas of spontaneously contracting cells, while fewer than 20% of EB derived 
from unmodified mESC or D3-eGFP cells displayed visible evidence of cardiomyocyte 
differentiation. Despite the absence of detectable GATA4 protein in D3G4-C, many more EB 
from this line developed areas of contracting cells compared to EB from either of the control cell 
lines (maximum 63% vs. 17% for the controls). This result may indicate that a small amount of 
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exogenous human GATA4 that is below the limit of detection by Western blot is sufficient to 
enhance cardiomyocyte differentiation from mESC. Alternatively, D3G4-C may have acquired 
other changes during its isolation and propagation that predisposed the cells to 
cardiomyogenesis, perhaps explaining the earlier appearance of contracting EB from this line 
than from D3G4-B (Figure 7). 
We used qRT-PCR to identify differences between d12 EB derived from D3G4-B and 
D3-eGFP in the mRNA levels of four cardiac-specific genes that are expressed at different stages 
of cardiomyogenesis (Table1). High levels of human GATA4 expression were detected in 
D3G4-B EB compared to the D3-eGFP control EB. In addition, increases of up to two orders of 
magnitude were observed for endogenous cardiac genes in EB from D3G4-B compared to D3-
eGFP EB and on balance, the expression pattern of these genes in D3G4-B EB was not unlike 
that in mouse heart.  
Together, our data strongly indicate that constitutive GATA4 overexpression can be a 
powerful driver of in vitro cardiac differentiation of mESC. Our findings are consistent with 
previous studies that extol GATA4 as the master regulator of cardiogenesis (13, 203). Because 
GATA4 is known to be expressed in vivo throughout all developmental stages from precardiac 
mesoderm to the adult heart (14), it is not unexpected that constitutive overexpression of GATA4 
can drive pluripotent stem cells toward a cardiac lineage without detrimental effects on 
terminally differentiated cardiomyocytes. However, the approach taken in this study involves 
permanent chromosomal modification of stably transfected stem cells, a system that is 
undesirable for the generation of clinically viable cardiomyocytes because of its oncogenic 
potential (85). Additionally, the use of a single D3G4 line for experimentation does not allow 
extrapolation to other GATA4-transduced pluripotent stem cell lines as each line divides at its 
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own pace and it is unclear how closely related different lines are to one another once they have 
been sufficiently expanded for differentiation and gene expression analyses. For example, we 
found that several lines, including D3G4-A, were much more prone to spontaneous 
differentiation than others. This may be due to differences in transgene integration sites that 
differentially affect transgene expression and may cause selection of different second-site events 
that in turn can lead to variations in growth rate and spontaneous differentiation between 
individual lines. 
While our study demonstrates that forced expression of GATA4 enhances the cardiogenic 
potential of mESC, implementation of strategies to express this and other cardiogenic factors 
through non-integrative mechanisms will be essential to produce a clinically relevant product for 
the treatment of cardiac ischemia. Our observation that human GATA4 induces expression of its 
mouse counterpart as well as other cardiac genes, directly or indirectly, suggests that an early 
pulse of ectopic GATA4 expression may be sufficient to commit daughter cells to the cardiac 
lineage and thus it will be worthwhile to determine whether transient ectopic GATA4 expression 
from a replication-defective, non-integrating viral vector can enhance cardiomyocyte production 
from pluripotent stem cells. The work described in the next chapters was aimed at determining 
whether transient expression of a powerful cardiac transcription factor like GATA4 from our 
vectors is capable of initiating a cascade of cardiac gene expression, conferring enhanced mESC 
cardiogenic potential.   
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4.0  GENERATION OF A JDΒΒ-BASED HSV VECTOR FOR THE 
DIFFERENTIATION OF EMBRYONIC STEM CELLS INTO CARDIOMYOCYTES 
4.1 INTRODUCTION 
Embryonic stem cells (ESC) are derived from the inner cell mass of the blastocyst-stage embryo 
and can grow indefinitely in culture. ESC possess two defining characteristics. They can self 
renew to produce identical daughter ESC, and they can differentiate to give rise to cells of all 
three germ layers, endoderm, ectoderm, and mesoderm, that are present from embryogenesis 
through adulthood. (73). Murine embryonic stem cells (mESC) are the best characterized of all 
pluripotent stem cells, and ever since their initial isolation in 1981 (74, 75), ways have been 
sought to intervene in their complex differentiation processes to enrich for cells of a particular 
lineage. Because cardiovascular disease is the largest cause of global morbidity and mortality 
(22), and the adult heart lacks the ability to regenerate functional cardiomyocytes, there is much 
interest in developing the technology to generate cardiomyocytes from in vitro differentiated 
pluripotent stem cells for use in cell-based heart therapy. 
Many different methods have been tested to enhance the cardiac differentiation of mESC. 
Most begin with the aggregation in suspension of ESCs to form embryoid bodies (EB), structures 
resembling a mouse embryo that contain a mixture of differentiating cells derived from the three 
germ layers (117).  Upon attachment to gelatin-coated plates, EB maintained in differentiation 
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media will typically form spontaneously contracting areas indicative of cardiomyocyte formation 
at a low frequency, a process influenced by a number of factors including the specific mESC line 
and culture conditions (116). The difficulty has been unraveling the events that lead to 
cardiomyogenesis and intervening to create a population highly enriched for cells with 
cardiogenic potential. 
Fluorescence-activated cell sorting (FACS) has been used successfully by a number of 
groups to sort EB cell populations for cardiac progenitor cells. Gordon Keller’s lab elucidated 
some of the earliest events in cardiomyogenesis and discovered that the time-dependent 
coexpression of Flk-1 and Brachyury marks a cell population highly enriched for cardiac 
progenitors (119, 122). Another group used FACS to obtain a population of cells from 5 day old 
EB that co-express CXCR4 and Flk-1 and has a dramatically increased capacity for 
cardiomyocyte differentiation (124). 
Culture conditions, gene transfer, and treatment with small molecules have also been 
used to drive pluripotent stem cells to differentiate toward a cardiac lineage. Induced Notch4 
expression (123), addition of VEGF to culture media (125), and small-molecule modification of 
BMP signaling (126-129) all successfully enhanced cardiomyocyte development. Although some 
of the transcription factors vital to cardiomyocyte differentiation have been identified, commonly 
used methods for gene transfer to pluripotent stem cells have limitations. Non-viral gene transfer 
methods such as electroporation or nucleofection require high DNA concentrations and large 
numbers of cells, and cell viability and transduction efficiency are often poor (204, 205). The use 
of viral vectors for gene delivery to pluripotent stem cells has many advantages over other 
methods, including high efficiency and low toxicity to host cells. Lentiviruses and retroviruses 
efficiently infect stem cells and express transgenes with low toxicity, but the fact that they 
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integrate into the host cell genome is a major deterrent to their use in cells for clinical translation 
(206, 207). Adenovirus and adeno-associated viral vectors infect stem cells inefficiently and 
exhibit poor transgene expression (208, 209). AAV, lenti- and retroviral vectors in addition have 
limited transgene capacity, precluding the delivery of large or multiple transgenes from a single 
vector.  
HSV vectors have many advantages for gene transfer to embryonic stem cells. They are 
easily rendered replication defective and strategic genome modifications can limit or prevent the 
expression of viral genes that are toxic to host cells. HSV has a large genome, much of which is 
not required for efficient infection or transgene expression, and therefore has ample room for 
large transgene cassettes. HSV vector JDββHE (132) is highly replication defective, containing 
deletions of two immediate early genes, ICP4 and ICP22, as well as a complete deletion of the 
internally repeated or “joint” sequences (JD, joint deleted). The promoters of the immediate early 
ICP0 and ICP27 genes are replaced with copies of the early (β) thymidine kinase gene promoter 
so that the toxic products of these genes are significantly expressed only in engineered cell lines 
that provide the essential ICP4 protein in trans for virus production. As a result of these and other 
modifications, the vector that has ample room for foreign sequences. ICP0 is a multi-functional 
protein with non-specific transactivating activity attributable to its ability to protect the viral 
genome against epigenetic silencing. The ICP0 promoter substitution in JDββHE reduces 
expression of the ICP0 100-fold in embryonic stem cells, limiting ICP0-mediated cytotoxicity, 
yet this low level generates enough ICP0 activity to support robust transgene expression (132). 
JDββHE transduction of mESC does not interfere with self renewal or mesoderm induction, as 
evidenced by normal expression of Brachyury and Flk-1 in EBs derived from mESC infected at 
MOIs of up to 100. Furthermore, expression of developmental transgenes from JDββHE 
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produced lineage-related gene expression changes in differentiating EB (132). For these reasons, 
we chose the JDββHE backbone for insertion of early cardiac transcription factors GATA4 and 
NKX2.5 in order to generate a vector that could drive mESC differentiation toward a cardiac 
lineage.  
GATA4 is one of the key regulators of cardiogenesis that is expressed throughout cardiac 
development and in the adult heart. It is co-expressed with NKX2.5 in the precardiac mesoderm 
where these two proteins interact to synergistically activate the transcription of numerous other 
cardiac genes, such as the genes for TBX5, α-MHC, and cTnT (141). We generated vector 
vββG4Nk by homologous recombination between the JDββHE genome and a GATA4-Nkx2.5 co-
expression cassette. Transduction of mESC with vββG4Nk induced the expression of murine 
cardiac-related genes, enhancing the cardiogenic potential of the cells as evidenced by a greater 
proportion of EB containing contracting cardiomyocytes following mESC infection with 
vββG4Nk than with JDββHE or mock infection. 
4.2 MATERIALS AND METHODS 
4.2.1 Cells and culture conditions  
ICP4 deficient HSV vectors were propagated on ICP4 complementing cells lines. 7b cells are 
Vero (African green monkey kidney) cells that contain the both the ICP4 and ICP27 coding 
sequences under control of their native promoters (170). U2OS-ICP4 cells are human 
osteosarcoma cells that contain the ICP4 coding sequence under control of its native promoter 
(169). 293T cells are a derivative of human embryonic kidney 293 cells that contain the SV40 T-
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antigen. All three cell lines were cultured in DMEM (Corning) supplemented with 10% FBS 
(GIBCO), 100 U/ml penicillin (Cellgro), and 100 μg/ml streptomycin (Cellgro). U2OS-ICP4 
cells were maintained under constant selection with 2 μg/ml puromycin (Sigma). 
D3 mouse embryonic stem cells (a gift from T.E. Smithgall, University of Pittsburgh) 
were cultured in DMEM (Corning) supplemented with 15% FBS (GIBCO), 1% non-essential 
amino acids (GIBCO), 1 mM sodium pyruvate (GIBCO), 100 U/ml penicillin, 100 μg/mL 
streptomycin, 0.1 mM 2-mercaptoethanol (GIBCO), and 1000 U/ml mouse LIF (Millipore) on 10 
centimeter dishes coated with 0.2% gelatin (Sigma). Media was exchanged daily and cells were 
passaged with trypsin every 2-3 days to maintain a state of self-renewal and minimize 
spontaneous differentiation. 
4.2.2 G4NkmCh cassette construction 
The G4NkmCh cassette was constructed in the commercially available pcDNA3.1(+)Hyg 
plasmid (Life Technologies). First, the 2.3 kb PvuII fragment was removed and the plasmid 
backbone self-ligated. Next, a PacI/NheI linker was added into the SapI site of the plasmid 
backbone to create additional unique sites for cloning. The CMV promoter was then replaced 
with the CAG promoter, which was derived from plasmid pPEP100 (kindly provided by P. 
Spear, Northwestern University) (194) as a 1.7 kb SpeI to EcoRI fragment. This fragment was 
inserted into the pcDNA plasmid that had been digested with the same enzymes. The resulting 
plasmid was called pcDNA-CAGp. Next human GATA4, human NKX2.5, and mCherry were 
PCR amplified with primers to add restriction sites and 2A sequences. Plasmids containing 
human GATA4 and NKX2.5 cDNAs were obtained from Open Biosystems. mCherry was derived 
from pEP-miR (Cell Biolabs). Briefly, GATA4 was PCR amplified with primers forward (F/) 
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F/EcoRI-GATA4 and reverse (R/) R/GATA4-T2A and Nkx2.5 cDNA was amplified with 
primers F/T2A-Nkx and R/Nkx-Xho. The resulting two PCR products were then gel purified and 
amplified together with primers F/EcoRI-GATA4 and R/Nkx-Xho to give a fragment that begins 
with an EcoRI restriction site followed by a start codon, the GATA4 coding sequence, the T2A 
sequence, the NKX2.5 coding sequence, and ending with an XhoI restriction site (EcoRI-
GATA4-T2A-Nkx2.5-XhoI) all in the same open reading frame (ORF). Plasmid pcDNA-CAGp 
and fragment EcoRI-GATA4-T2A-Nkx2.5-XhoI were each cut with EcoRI and XhoI and the 
fragment was ligated into the plasmid backbone to give rise to plasmid pG4Nk.  
In the final step, mCherry was amplified with primers F/Xho-E2A-mCherry and 
R/mCherry-PmeI, resulting in a fragment beginning with an XhoI restriction site, followed by 
the E2A sequence, the mCherry coding sequence, and ending with a PmeI restriction site (XhoI-
E2A-mCherry-PmeI). This fragment and plasmid pG4Nk were digested with XhoI and PmeI and 
the mCherry fragment was ligated into the plasmid, giving rise to plasmid pG4NkmCh, with 
GATA4, NKX2.5, and mCherry all in one continuous ORF. Sequences were obtained for all parts 
of the cassette (Genewiz) to verify that no errors occurred during PCR amplification. 
 
 
 
Table 4. Primer sequences for construction of G4NkmCh cassette 
 
 
F/EcoRI-GATA4 ccacaGAATTCGTAATAGGATAGCGACatgtatcagagcttggccatg 
 
R/GATA4-T2A CCTCGACGTCACCGCATGTTAGCAGACTTCCTCTGCCCTCTCCGGAGCCc
gcagtgattatgtccccgtgac 
 F/T2A-Nkx 
 
GAAGTCTGCTAACATGCGGTGACGTCGAGGAGAATCCTGGCCCAatgttcccc
agccctgctctcacg 
 R/Nkx-Xho 
 
CTGTAGCTCGAGccaggctcggataccatgcag 
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F/Xho-E2A-mCherry 
 
CTGAGCCTCGAGGGTCAATGTACTAACTACGCTTTGTTGAAACTCGCTGG
CGATGTTGAAAGTAACCCCGGTCCTatggtgagcaagggcgaggaggat 
 R/mCherry-PmeI 
 
CTGTGGGTTTAAACctatcatgggtccttgtacagctcg 
 
 
 
Underlined sequences are restriction sites, green designates start codons, blue designates 2A sequences 
(italics for partial 2A), and red designates stop codons. 
 
4.2.3 Vector vββG4Nk construction 
Vector JDββHE (132) was engineered to contain the G4NkmCh cassette via homologous 
recombination in ICP4/ICP27 complementing 7b cells through transfection and infection as 
previously described (170). The recombination plasmid was constructed as follows. The 
G4NkmCh cassette was isolated from pG4NkmCh by digestion with NheI, filling in of the 5’ 
overhang, digestion with SpeI, and gel purification of the 5.2 kb band containing the cassette. In 
parallel, UL41 targeting plasmid pH41 (210) was digested with BamHI, filling in of the 5’ 
overhang, digestion with SpeI, and the G4NkmCh cassette was ligated into the pH41 backbone 
to generate UL41 targeting plasmid pH41G4NkmCh. The plasmid was linearized by digestion 
with ClaI and gel purified for transfection. 7b cells that had been plated in 6 well plates 24 h 
prior and were approximately 75% confluent were transfected with 3μg linearized 
pH41G4NkmCh using Lipofectamine LTX (Invitrogen) according to the manufacturer’s 
protocol. 24 h post transfection, the 7b cells were infected in a monolayer in 6 well plates with 
JDββHE at an MOI of 0.04 or 0.15 pfu/cell in 1 ml serum free DMEM at 37°C with 5% CO2 for 
2 h with occasional rocking. 2 ml serum free media was added to the wells and the plates were 
incubated at 33°C. The virus was allowed to replicate until nearly all of the cells in a well 
demonstrated cytopathic effects (CPE), and the cells and virus were collected in their media, 
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sonicated, aliquoted, and frozen at -80°C. Fresh 7b cells were plated in 6 well plates and infected 
at a range of concentrations with the virus collected from the transfection/infection. The virus 
was allowed to replicate for 48-72 h. Wells with widely spaced plaques were identified, and 
plaques that expressed both eGFP and mCherry were picked with a pipette under a fluorescence 
microscope and serially diluted on 7b cells in 96 well plates to obtain clones of vββG4Nk. These 
clones were plaque purified three times by choosing wells with a single eGFP+/mCherry+ 
recombinant, using the virus from the plaque to infect fresh cells in suspension, plating serial 
dilutions of these cells, and repeating until a clonal population of virus was obtained as indicated 
by 100% eGFP-mCherry co-expression. 
4.2.4 Large scale production of vββG4Nk 
To obtain a large quantity of high titer virus to complete these studies, vββG4Nk production was 
scaled up from a 96 well plate to 10-20 T150 tissue culture flasks. For large scale production, 
U2OS-ICP4 cells were plated in the desired number of T150 flasks and when the cells became 
confluent, they were infected in a monolayer with one isolate of the plaque purified virus at an 
MOI of 0.1 pfu/cell. The cells were infected in 10 ml serum free DMEM (Corning) per T150 
flask with occasional gentle agitation for 2 h at 37°C. After two hours, 10 ml serum free DMEM 
was added to each flask, and the infected cells were incubated at 33°C to allow for maximum 
virus survival without cell overgrowth until the entire flask reached CPE, typically 7-10 days 
post infection (dpi). The media was then collected and the dead cells were spun out in a table top 
centrifuge at 3,000 rpm for 10 min at 4°C. The supernatant containing the virus was filtered 
through a 0.8 μm Versapor membrane (PALL Corporation), and then concentrated by multiple 
cycles of high speed centrifugation at 19,500 rpm for 45 min at 4°C. All of the supernatant was 
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spun down into two tubes, and the resulting viral pellets were each gently resuspended in 200 μl 
phosphate buffered saline (PBS) with 10% glycerol by gentle agitation at 4°C for 24-48 h. The 
resuspended pellets were combined, divided into 5-20 μl aliquots, and stored at -80°C. One 
aliquot was then titered by infecting U2OS-ICP4 cells with serial dilutions for 2 h at 37°C, 
overlaying with high density DMEM containing 5% methyl cellulose (Sigma), and incubating at 
33°C until the plaques were large enough to count under the microscope, typically 48-72 hpi.  
4.2.5 Western blot analysis 
GATA4 and NKX2.5 expression from pG4NkmCh was confirmed by transfection of 293T cells 
with the plasmid using Lipofectamine LTX (Invitrogen) according to the manufacturer’s 
protocol and collection of total cellular protein 24 h later. GATA4 and NKX2.5 expression from 
vββG4Nk was confirmed by infection of U2OS-ICP4 cells at a range of MOIs (0.005 – 0.5) and 
protein collection at 24 hpi. Cell lysates were harvested in RIPA lysis buffer supplemented with 
protease inhibitors (Roche). Proteins were separated on a 10% polyacrylamide-SDS gel and 
transferred by semi-dry transfer onto PVDF membranes. The membranes were washed in Tris-
buffered saline (TBS) and blocked for 1 h at room temperature in TBS-T (20 mM Tris, 0.5 M 
NaCl [pH 7.5] plus 0.5% Tween 20) supplemented with 10% nonfat dry milk. Antibodies diluted 
in blocking buffer were reacted with the membranes overnight at 4°C, washed 3 times for 10 min 
each in TBS-T, and reacted with horseradish peroxidase-conjugated secondary antibody diluted 
1:10,000 in blocking buffer for 1 h at room temperature. The bound Igs were revealed by 
enhanced chemiluminescence (Thermo Scientific). Antibodies are listed in Table 2. 
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4.2.6 Embryoid body assay 
D3 mouse embryonic stem cells were infected in suspension with JDββHE or vββG4Nk or mock 
infected in a small volume in Eppendorf tubes at 37°C with continuous rotation for 1-2 hours. 
Infected cells were diluted in mESC media without LIF at a concentration of 4x104 cells/ml. 20 
μl drops of cells were pipetted onto the lid of a petri dish, and the lid was inverted over the dish 
that contained 30 ml sterile water to prevent the drops from evaporating. The cells were 
incubated at 37°C with 5% CO2 and allowed to aggregate to form embryoid bodies (EB) and 
differentiate for two days in hanging drops. After 48 h in hanging drops, the EB were pipetted 
one per well into 48 well plates, each well containing 500 μl mESC media without LIF. The EB 
were observed daily for the appearance of spontaneously contracting cells, and the number of 
wells containing these cells was recorded each day. 
4.2.7 RNA extraction and quantitative RT-PCR analysis 
Total RNA was extracted from D3 mES cell lines and embryoid bodies using Qiagen RNeasy 
Plus mini kit (Qiagen) according to the manufacturer’s protocol.  
 Total RNA was extracted from the heart of an adult mouse as follows. The mouse was 
humanely sacrificed and the heart dissected out and immediately placed into 2 ml RNAlater 
(Qiagen) to stabilize and protect RNA. The heart was then minced with two razor blades and 
transferred into a Dounce homogenizer in 2 ml TRIzol reagent (Life Technologies) and 
mechanically ground. Remaining solids were pelleted and discarded, and 200 μl chloroform was 
added to the supernatant. The solution was transferred into two 1.5 ml phase-lock tubes and 
centrifuged for 15 min at 14,000 rpm at 4°C. The aqueous phase was transferred into a gDNA 
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eliminator column and the RNA extracted using an RNeasy Plus mini kit (Qiagen) according to 
the manufacturer’s protocol. 
Reverse transcription was performed on 1-2 μg RNA in 20 μl final volume using random 
decamers as first strand primers with Ambion’s RETROscript Kit (Ambion), and the resulting 
cDNA was diluted 1:10 for quantitative RT-PCR analysis. 
Primers were obtained from Invitrogen. Primer sequences and references for qPCR are 
listed in Table 3. qPCR was performed using LightCycler SYBRgreen Master Mix (Roche) or 
TaqMan Gene Expression Assays (Invitrogen) and a Step One Plus Real-Time PCR System 
(Applied Biosystems). Cycling conditions were 95°C for 10 min followed by 40 cycles of 95°C 
for 15 sec and then 60°C for 1 min. Each cDNA was analyzed in triplicate, and the results for the 
three wells were averaged. Threshold cycle (Ct) values were used to calculate changes in gene 
expression using the 2-ΔΔCt method (195). Expression levels were normalized to HPRT mRNA 
for SYBRgreen or 18S ribosomal RNA levels for TaqMan, and expressed relative to uninfected 
D3 mESC. 
 
4.3 RESULTS 
4.3.1 G4NkmCh cassette construction and confirmation 
A cassette designed for recombination with the JDββHE vector genome in order to express 
human GATA4, NKX2.5, and mCherry as a marker for gene expression was constructed as 
detailed in Materials and Methods. The expression of these three genes is controlled by the CAG 
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promoter. GATA4, NKX2.5, and eGFP are translated from a single multigene ORF by the 
inclusion of in frame 2A sequences between genes (Table 5). 2A sequences are short, 18-22 
amino acid sequences derived from small RNA viruses, and allow the generation of multiple 
proteins from a single transcript (211). They function through a “ribosomal skipping” 
mechanism between the highly conserved glycine and proline residues at the carboxyl terminus 
of the 2A sequence, leaving a tag at the carboxyl end of the upstream protein and adding the 
terminal proline residue to the downstream (“2B”) sequence without impairing the 2B translation 
efficiency (212). In this construction, we took advantage of two known 2A sequences, T2A and 
E2A. Two distinct sequences were used to minimize the possibility of recombination. The 
advantage of using 2A sequences to form polycistronic transcripts is that they are highly efficient 
and allow for stoichiometric expression of individual transgene products while avoiding the need 
for separate promoters. This 2A system allows recombination of three separate transgenes into 
JDββHE through a single recombination event.  
 
Table 5. 2A sequences used in HSV vectors and their ‘skipping’ sites. 
 
 
Family Example Designation Amino Acid Sequence 
   
2A "skipping" site    
Picornaviridae FMDV F2A VKQTLNFDLLKLAGDVESNPG    P 
 
ERAV E2A QCTNYALLKLAGDVESNPG    P 
Tetraviridae TaV T2A EGRGSLLTCGDVEENPG    P 
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Following PCR amplification of human GATA4 and NKX2.5 cDNAs with primers to add 
the necessary 2A sequences and restriction sites, the cassette was assembled into a shuttle 
plasmid (Figure 9A) and sequenced. The sequences were verified and plasmid pG4NkmCh was 
transfected into 293T cells. Cell lysates were collected 24 h post transfection, and Western 
blotting was performed to confirm expression of the three proteins.  
 
 
 
 
Figure 9. Plasmid pG4NkmCh and transgene expression upon transfection into 293T cells. 
A schematic of the structure of the transgene cassette in plasmid pG4NkmCh is shown in (A). The CAG 
promoter drives expression of three transgenes, GATA4, NKX2.5, and mCherry, with T2A and F2A 
sequences separating them. (B) mCherry expression in 293T cells transfected with plasmid pG4NkmCh 
24 h post transfection. (C) Expression of both GATA4 and NKX2.5 proteins from pG4NkmCh 24 h post 
transfection in 293T cells is revealed in a Western blot with a primary antibody against the 2A peptides. 
Expression of GATA4 and NKX2.5 was also demonstrated through Western blotting with specific 
GATA4 (D) and NKX2.5 (E) antibodies. The two lanes for pG4NkmCh in (C-E) represent two separate 
clones of pH41G4NkmCh transfected independently into 7b cells. G4 only (D) represents 293T cells 
transfected with a plasmid that expresses GATA4 but not NKX2.5 from the CMV promoter. 
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mCherry expression was readily observed by fluorescence microscopy in 293T cells 
transfected with pG4NkmCh (Figure 9B). Using an antibody against the carboxy-terminal 2A 
peptides, proteins of the expected size for GATA4 (~50 kDa) and NKX2.5 (~40 kDa) were 
detected in lysates of 293T cells transfected with pG4NkmCh (Figure 9C). Likewise, GATA4 
(Figure 9D) and NKX2.5 (Figure 9E) were detected by their individual monoclonal antibodies on 
separate Western blots. The NKX2.5 antibody consistently detects additional larger proteins on 
Western blots aside from the ~40 kDa NKX2.5 protein.  It is unlikely that these are fusion 
proteins between NKX2.5 and GATA4 or mCherry since no bands of the corresponding sizes 
were detected on the individual blots for GATA4 (Figure 9C, no ~70-kDa or ~45-kDa bands) or 
mCherry (data not shown), or the blot probed with the anti-2A peptide antibody. 
4.3.2 Recombination of the G4NkmCh cassette into JDββHE and growth of vββG4Nk 
The G4NkmCh cassette was cloned into the UL41 targeting plasmid pH41 (210) to create 
plasmid pH41G4NkmCh (Figure 10A). This plasmid has long regions of homology (“homology 
arms”) to the viral UL41 locus on both ends of the transgene cassette. These homology arms 
contain the sequences flanking the UL41 deletion in the JDββHE genome, 1.7 kb of the 5’ flank 
and 1.5 kb of the 3’ flank, to allow for homologous recombination of G4NkmCh into the vector. 
Plasmid pH41G4NkmCh was transfected into 7b cells and cell lysates were collected 48 h post 
transfection to verify that GATA4 and NKX2.5 proteins were expressed appropriately within the 
context of the surrounding UL41 sequences.  
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Figure 10. Schematic of and transgene expression from UL41 targeting plasmid pH41G4NkmCh. 
7b cells were transfected with pH41G4NkmCh (A), cell lysates collected, and Western blots were 
performed to demonstrate expression of GATA4 (B) and NKX2.5 (C) proteins. Lysates from 
untransfected 7b cells and 7b cells transfected with RFP expression plasmid pH41RFP were included as 
negative controls. 7b cells transfected with pG4NkmCh were included as positive controls for both 
GATA4 and NKX2.5 expression. The two lanes for pH41G4NkmCh in (B) and (C) represent two 
separate clones of pH41G4NkmCh transfected independently into 7b cells. 
 
  
 
 
7b cells transfected with pH41G4NkmCh clearly expressed mCherry 24-48 h post 
transfection when examined by fluorescence microscopy, and red fluorescent protein (RFP) 
expression was evident in cells transfected with control plasmid pH41RFP containing the RFP 
gene under control of the CMV promoter in plasmid pH41 (not shown).  Western blotting 
demonstrated that GATA4 (Figure 10B) and NKX2.5 (Figure 10C) were expressed in 
pH41G4NkmCh-transfected 7b cells at the correct sizes, co-migrating with their counterparts 
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from pG4NkmCh-transfected cells; no products were observed in untransfected or pH41RFP-
transfected cells. With this verification completed, the G4NkmCh cassette was recombined into 
HSV vector JDββHE in ICP4/ICP27-complementing 7b cells using a transfection/infection 
protocol adapted from reference (213), as described below.  
ClaI was used to linearize pH41G4NkmCh in the plasmid backbone outside of the insert 
(Figure 10A). Linearized pH41G4NkmCh was transfected into 7b cells, and 24 h post 
transfection the cells were infected with JDββHE. The transfected/infected 7b cells were 
incubated at 33°C to maximize virus yield. Once all of the cells showed signs of CPE (Figure 
11A), the virus was collected and used to infect fresh 7b cells in 6 well plates at a range of 
dilutions to obtain large, widely spaced plaques in at least one well (Figure 11B, left). 
Approximately 20 well-isolated plaques that co-expressed eGFP (from the deleted ICP4 locus of 
JDββHE) and mCherry (from the G4NkmCh cassette) were picked under a fluorescence 
microscope and serial dilutions were used to infect 96 well plates of fresh 7b cells (Figure 11C). 
Many recombinant plaques were identified in this first round of limiting dilution and several 
were purified through two more rounds to obtain clonal populations of vββG4Nk (Figure 11D). 
One clonal isolate along with JDββHE was grown in multiple T150 flasks of 7b cells to produce 
enough virus for experimentation. Titers of both viruses were between 2x106 and 8x106 pfu/ml. 
Final vector configurations are shown in Figure 12. 
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Figure 11. Recombination of the G4NkmCh cassette into JDββHE to form vββG4Nk 
(A) 7b cells 48 h post pH41G4NkmCh transfection, 24 hpi with JDββHE at different MOIs. Expression of 
mCherry (left panels) and eGFP (right) was visualized by fluorescence microscopy. (B) After the cells 
from (A) were killed by the virus, fresh 7b cells were infected with dilutions of the virus from the 
transfection/infection, showing the presence of both recombinant (red + green) and non-recombinant 
(green only) viruses. (C) Schematic of the plaque purification protocol used to obtain clonal isolates of 
vββG4Nk. Red, recombinants (red + green); green, JDββHE. See text. (D) Plaque from a clonal isolate 
of vββG4Nk showing co-expression of eGFP and mCherry. 
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Figure 12. Description of recombinant HSV vectors 
Virus genomes are shown schematically with genes labeled at the approximate location in the vectors (not 
to scale). Deletions in JDββHE are depicted in black, and IE to E gene promoter substitutions (β) in 
yellow (132). Transgenes are colored and labeled. For vector vββG4Nk, the entire transgene cassette 
shown below the vector diagram is located within the UL41 locus. 
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Figure 13. vββG4Nk replication on ICP4 complementing and non-complementing cells 
Vero and U2OS-ICP4 cells were infected with three separate isolates of vββG4Nk and visualized at 6 dpi 
by fluorescence microscopy. 
 
 
 
4.3.3 Characterization of vββG4Nk 
To confirm that vββG4Nk does not replicate in non-complementing cells, both non-
complementing Vero cells and ICP4-complementing U2OS-ICP4 cells were infected with three 
different vββG4Nk isolates. The infected cells were observed for 6 dpi. While vββG4Nk formed 
many plaques on ICP4-complementing cells, no plaques were observed on Vero cells (Figure 
13).  
 Transgene expression from vββG4Nk was confirmed in ICP4 complementing U2OS cells 
by infecting the cells at three different MOIs (0.005 – 0.5 pfu/cell), collecting cell lysates 24 hpi, 
and performing a Western blot with primary antibodies against GATA4 and NKX2.5. The blots 
demonstrated that both GATA4 (Figure 14A) and NKX2.5 (Figure 14B) were expressed from 
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vββG4Nk in an MOI-dependent manner. The 2A sequences functioned correctly when expressed 
from the HSV vector, allowing translation of separate correctly sized proteins. A smaller product 
is always detected with the GATA4 antibody in Western blots of lysates from HSV-infected cells 
(Figure 14A). This product is independent of GATA4 expression. It is also seen in cells infected 
with HSV vectors that do not express GATA4 (data not shown). Thus this GATA4 antibody 
cross-reacts with a protein that is either expressed from HSV or induced by HSV infection. 
 
 
 
 
 
 
Figure 14. Expression of transgenes in U2OS-ICP4 cells infected with vββG4Nk at different MOIs 
Western blots of lysates collected from ICP4-complementing U2OS cells infected with vββG4Nk and 
probed with GATA4 (A) and NKX2.5 (B) antibodies. Positive control in the first lane (+) is 293T cells 
transfected with pG4NkmCh, negative control in the second lane (-) is mock-infected U2OS-ICP4 cells. 
 
 
 
Expression of GATA4 and NKX2.5 transgenic proteins was detected by Western blot 
lysates from mESC infected with vββG4Nk at MOIs of 3 and 10, but the GATA4 bands were 
less clear than for NKX2.5 on these blots (Figure 15). Although Western blots using this GATA4 
antibody nearly always show bands with greater intensity than the antibody for NKX2.5 on the 
 73 
same samples (see Figure 10 and Figure 14), in this blot the opposite is true. We are unsure of 
the cause of this anomaly. Transduction of mESC with vββG4Nk could be clearly observed by 
fluorescence microscopy as co-expression of eGFP and mCherry after infection with vββG4Nk 
at MOI=1 (Figure 16). 
 
 
 
 
 
 
Figure 15. GATA4 and NKX2.5 transgene expression in mESC by Western blot 
Lysates were collected from Ø-, JDββHE-, and vββG4Nk-infected mESC, proteins separated by SDS-
PAGE, and blots probed with antibodies against GATA4 and Nkx2.5. 
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Figure 16. mESC infected at MOI=1 with vββG4Nk express eGFP and mCherry at 24 hpi 
D3 mESC were infected in suspension at an MOI of 1 with JDββHE, vββG4Nk, or mock-infected and 
plated in gelatin-coated 6 well plates. The top row shows bright field pictures of the cells, the middle row 
is eGFP expression from the deleted ICP4 locus in JDββHE and vββG4Nk, and the bottom row is 
mCherry expression from the G4NkmCh cassette in vββG4Nk.  
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4.3.4 Transduction of mESC with vββG4Nk induces endogenous cardiac gene expression 
In the preceding experiments, we demonstrated that vββG4Nk can efficiently transduce mESC 
and express transgenes GATA4, NKX2.5, mCherry, and eGFP. Next we investigated the 
duration of transgene expression and its effects on the expression of endogenous cardiac genes 
using RT-PCR and qRT-PCR.  
First we checked the specificity of our human GATA4 and NKX2.5 PCR primers. U2OS-
ICP4 cells were transfected with either pG4NkmCh or with plasmids that express GATA4 or 
NKX2.5 alone, were mock-infected or infected with vββG4Nk. RNA was collected 48 h post 
transfection or infection, reverse transcribed, and the cDNA used for PCR with the human-
specific GATA4 and NKX2.5 primers. The PCR products were run on a 2% agarose gel. The 
primers for each transgene amplified a product of the expected size only in cells treated with the 
corresponding gene. A PCR-amplified GATA4 product was detected only in cDNA from 
pG4NkmCh-transfected cells, cells transfected with the plasmid that expressed GATA4 alone, 
and cells infected with vββG4Nk. An NKX2.5 product was only amplified from cDNA of cells 
transfected with pG4NkmCh, the plasmid that expressed NKX2.5 alone, and cells infected with 
vββG4Nk (Figure 17A). 
Mouse-specific primer sets were used for semi-quantitative RT-PCR on RNA collected 
from mESC, vββG4Nk-infected mESC, and d11 EB with many spontaneously contracting foci 
as a positive control for cardiac-specific genes. mESC infected with vββG4Nk were allowed to 
grow in a 6 well plate for 48 h in media containing LIF to inhibit spontaneous differentiation 
prior to RNA collection. The RT-PCR results demonstrated that human GATA4 and NKX2.5 
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transgene RNA could only be detected from vββG4Nk-infected mESC, and indicated that 
expression of endogenous cardiac genes, including mouse Gata4 and Nkx2.5, cTnI, and Mlc2a, 
were upregulated in vββG4Nk-transduced mESC compared to control mESC (Figure 17B). 
Since cTnI and Mlc2a are typically expressed in more mature cardiac cell types (Table 1), the 
data indicated that even when cultured with LIF, cardiac programming may begin in mESC 
immediately following infection with vββG4Nk. They also confirmed that the primers for human 
GATA4 and NKX2.5 were specific as no product was detected in d11 EB while the primers for 
mouse Gata4 and Nkx2.5 did amplify a product.  
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Figure 17. Semi-quantitative RT-PCR for cardiac-specific genes  
Products from semi-quantitative RT-PCR run on 2% agarose gels. (A) U2OS cells were transfected with 
plasmids expressing both GATA4 and NKX2.5 (G4Nk), GATA4 alone (G4), or NKX2.5 alone (Nk), or 48 
hpi with vββG4Nk. Products from RT-PCR with human-specific GATA4 and NKX2.5 primers were run 
on a 2% agarose gel. (B) Endogenous cardiac gene expression was examined by RT-PCR in vββG4Nk-
infected mESC 48 hpi and compared to undifferentiated mESC and 11 d old EB containing many mature 
cardiomyocytes. RT-PCR products were amplified with cardiac gene-specific primers and run on a 2% 
agarose gel. 
 
 
 
To quantitatively assess changes in gene expression, quantitative RT-PCR (qRT-PCR) 
was used to compare transgene and endogenous RNA expression in mESC that were mock-
infected, infected with JDββHE, or infected with vββG4Nk at MOI=1. Cells were maintained in 
6 well plates with mESC media plus LIF. RNA was collected 48 hpi and reverse transcribed. 
Mouse heart cDNA was included as a control for cardiac gene expression. Each sample was 
 78 
measured in triplicate, and the Ct values were averaged. Relative mRNA levels were calculated 
using the 2-ΔΔCt method (195) and normalized to GAPDH or HPRT mRNA levels and are 
presented in Figure 18 relative to uninfected mESC. We measured the expression levels of Oct4, 
a pluripotency marker, in infected mESC to determine whether transduction with JDββ-based 
vectors alone pushes mESC to differentiate. Expression of Oct4 was essentially unaffected in 
mESC transduced with JDββHE or vββG4Nk compared to mock infected mESC (Ø). Oct4 
mRNA was not detected in the terminally differentiated cells of the adult mouse heart. High 
levels of human GATA4 expression were observed in mESC transduced with vββG4Nk but not 
mock- or JDββHE-infected mESC or mouse heart. Abundant GATA4 transgene expression was 
detected only in vββG4Nk-transduced mESC, confirming the species-specificity of our GATA4 
primers. No amplification of human NKX2.5 cDNA was observed from vββG4Nk-infected 
mESC although we knew from the earlier Western blot and semi-quantitative PCR data that the 
gene is expressed (Figure 17). The polymerases used in these two experiments were different, 
Pfx for semi-quantitative PCR and the proprietary, thermostable polymerase of the SYBRgreen 
real-time PCR master mix (Life Technologies) for the qRT-PCR reactions, potentially 
accounting for the discrepancy. GATA4 is expressed early in cardiac development, and its 
expression continues in mature cardiomyocytes. Our data shows that endogenous mouse Gata4 
was upregulated in response to vββG4Nk- but not JDββHE-transduction, consistent with 
published reports that GATA4 binds to its own promoter to upregulate its expression (141). 
Endogenous Gata4 expression was greater from vββG4Nk-transduced mESC than mouse heart. 
A similar upregulation of endogenous Nkx2.5 in response to vββG4Nk-transduction was not 
observed although GATA4 can reportedly upregulate NKX2.5 expression (141). Contrary to 
what was suggested by the semi-quantitative PCR data, cTnI and Mlc2a, mRNAs that encode 
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cardiomyocyte structural proteins (Table 1), were not detected by qRT-PCR in any of the mESC 
samples but were present in mouse heart (Figure 18). 
 
 
 
 
 
 
Figure 18. Gene expression in mock-, JDββHE-, and vββG4Nk-infected mESC by qRT-PCR 
qRT-PCR data is shown for mESC 48 hpi with JDββHE, vββG4Nk, or mock-infected and mouse heart 
cDNA. Gene expression is normalized to HPRT or GAPDH mRNA and fold change is expressed relative 
to uninfected mESC. 
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  To confirm the specificity of the mouse Gata4 primers and thereby verify that 
endogenous Gata4 is upregulated in mESC in response to infection with vββG4Nk, we 
completed additional PCR with this primer set on cDNA from vββG4Nk-infected mESC. A 
prominent product of the expected size (72 bp) was detected by agarose gel electrophoresis 
(Figure 19A), isolated, and cloned. Sequencing confirmed that the amplified product was derived 
from the 5’ UTR of mouse Gata4 mRNA that has no sequence homology with its human 
ortholog (Figure 19B) or with vector vββG4Nk.  
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Figure 19. PCR product amplified using mouse Gata4 primers on cDNA from vββG4Nk-infected 
mESC 
(A) 72 bp PCR product amplified from mESC 48 hpi with vββG4Nk run on a 2% agarose gel. (B) 
Sequencing results of this product show that it is located in the 5’ UTR of mouse Gata4 mRNA.  
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To determine whether transduction of mESC with these vectors affects gene expression 
throughout differentiation, mESC were infected in suspension for 1 h with 1 pfu/cell of vector 
JDββHE, vββG4Nk, or mock-infected (Ø). The cells were differentiated into EB using the 
hanging drop method and plated one EB per well in 48 well plates for attachment and outgrowth. 
RNA was harvested every 3 d for a total of 15 d, and then reverse transcribed. qPCR utilizing 
TaqMan primers and probes was carried out on the resulting cDNA. All data was normalized to 
18S rRNA and is presented in Figure 20 as fold change from time-matched mock-infected EB. 
Expression of the human GATA4 and NKX2.5 transgenes was examined, along with expression 
of cardiogenic mouse genes that are active throughout differentiation, including Gata4, Nkx2.5, 
Mef2c, Tbx5, and cTnI (Table 1). While there was substantial noise in the data, a few important 
trends were evident from this experiment. Endogenous Gata4 was upregulated in differentiating 
EB made from vββG4Nk-infected mESC (vββG4Nk EB) but not in EB from JDββHE-infected 
mESC (JDββHE EB). Expression of the GATA4 and NKX2.5 transgenes was prominent at 3 dpi 
and remained detectable at 6 dpi (GATA4). Expression of cTnI, a protein critical for the 
contraction of heart muscle, appeared to be upregulated in d15 vββG4Nk EB although the 
change was small (Figure 20). 
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Figure 20. Time course qRT-PCR data from EB from mock-, JDββHE-, and vββG4Nk-infected 
mESC 
Gene expression data was normalized to 18S rRNA and is expressed relative to mock-infected time-
matched EB. Fold change in mRNA levels is expressed as the average of three independent wells for each 
gene and condition at 3, 6, 9, 12, and 15 days after the onset of differentiation. 
 
 
 
4.3.5 Transduction of mESC with vββG4Nk prior to differentiation results in a larger 
population of EB with spontaneously contracting patches 
The data described in section 4.4.4 indicated that transduction of mESC with vββG4Nk leads to 
alterations in cardiac-specific gene expression when compared to Ø- or JDββHE-infected mESC. 
Specifically, an increase in the expression of endogenous Gata4, Mlca, and cTnI was observed in 
mESC following transduction with vββG4Nk (Figures 17 and 18). Finally, we examined whether 
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there were observable physical differences in EB resulting from vββG4Nk transduction. 
Specifically we were interested in determining whether mESC infected with vββG4Nk and then 
differentiated into EB contained a higher percentage of spontaneously contracting patches, a 
phenotype indicative of cardiomyocyte differentiation. 
D3 mESC were infected at 1 pfu/cell with JDββHE, vββG4Nk or mock-infected in 
suspension for 1 h. After infection, cells were diluted in mESC media without LIF, and were 
allowed to aggregate at the bottom of hanging drops to form EB. The EB were differentiated in 
hanging drops for 48 h and were then individually pipetted one per well into 48 or 96 well plates 
for attachment and outgrowth. At least 48 EB from each condition for each experiment were 
observed under the microscope for 2 weeks after plating. Spontaneously contracting patches of 
cells appeared between 8 and 14 days after the onset of differentiation. Results were recorded on 
the day when the most contracting EB were present. 
The absolute percentage of EB containing contracting cell patches varied widely between 
repetitions of the same experiment, likely due to inconsistencies in the mESC used to make EB 
(passage number, presence of spontaneously differentiated cells, etc.). However there was an 
obvious and consistent increase in the percentage of vββG4Nk EB that developed spontaneously 
contracting cells compared to Ø EB or JDββHE EB. This differentiation experiment was 
repeated five times, and data from each experiment is plotted in Figure 21A. The averages for all 
of the experiments is shown in Figure 21B. While the absolute percentage of EB with contracting 
cell patches varied between experiments (Figure 21A), it is clear when all of the data are taken 
together that vββG4Nk EB consistently contained more spontaneously contracting areas of 
cardiomyocyte differentiation than Ø EB or JDββHE EB (Figure 21B). 
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Figure 21. vββG4Nk-infected mESC make a greater percentage of EB containing cardiomyocytes 
(A) The percentages of EB containing patches of spontaneously contracting cells are plotted for Ø EB, 
JDββHE EB, and vββG4Nk EB in 5 independent experiments. (B) The averages of the 5 independent 
differentiation experiments from (A) are shown. * p < 0.05.  Data were analyzed using Students t test. 
Error bars indicate SEM. 
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4.4 DISCUSSION 
JDββHE is a replication defective HSV vector that efficiently transduces mESC, is non-toxic, 
and does not interfere with EB formation or differentiation into the three germ layers (132). In 
this report, we described the engineering of JDββHE-based vector vββG4Nk to express two early 
cardiac transcription factors, GATA4 and NKX2.5, plus mCherry as a reporter gene, from the 
UL41 locus of the HSV genome. These three transgenes are expressed in one cassette from a 
single CAG promoter with 2A “ribosomal skipping” sequences between the transgenes that 
enabled translation of three distinct proteins.  
GATA4 and NKX2.5 are cardiac-specific transcription factors that are essential for heart 
formation (136, 138). We expressed these genes from vββG4Nk in mESC to enhance the 
differentiation of these cells toward a cardiac lineage. qRT-PCR data showed that 48 h after 
transduction with vββG4Nk, mESC maintained in media with LIF expressed similar levels of 
Oct4 to mock-transduced or JDββHE-transduced mESC, indicating that the vector does not 
interfere with the pluripotency of the cells. vββG4Nk-transduced mESC expressed high levels of 
endogenous (mouse) Gata4 compared to mock (Ø)- and JDββHE-transduced controls and also 
compared to mouse heart cDNA, demonstrating that expression of the human GATA4 and 
NKX2.5 transgenes from this vector successfully induced expression of endogenous cardiac 
genes. Semi-quantitative RT-PCR indicated that in addition to endogenous Gata4, endogenous 
Nkx2.5, Mlc2a, and cTnI were also upregulated in mESC transduced with vββG4Nk. 
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vββG4Nk does not express the essential immediate early gene ICP4, and therefore cannot 
replicate in mESC. Virus genomes are quickly diluted in these rapidly dividing cells and thus we 
relied on a pulse of transgene expression to set into motion a cascade of cardiac gene expression 
events that could effect changes in differentiating EB long after mESC transduction. vββG4Nk 
expresses only low levels of ICP0, mitigating its toxicity while still allowing robust expression 
of GATA4 and NKX2.5 proteins in mESC. Transgene mRNA could be detected in mESC 
transduced with 1 pfu/cell for at least 6 dpi in differentiating EB, and upregulation of 
endogenous cardiac-specific genes continued even after transgene expression could no longer be 
detected by qRT-PCR. Finally, we found that transduction of mESC with vββG4Nk followed by 
differentiation in EB significantly increased their cardiac differentiation such that many more 
vββG4Nk EB contained large clusters of spontaneously contracting cardiomyocytes than Ø EB 
or JDββHE EB. While the magnitude of the increase varied between experiments, the percentage 
of contracting vββG4Nk EB was consistently greater than that of control EB in each of the five 
differentiation experiments, and when averaged clearly showed that approximately 5 times more 
vββG4Nk EB contained visible cardiomyocyte differentiation than Ø EB or JDββHE EB. 
The data reported in this chapter demonstrates that short-term GATA4 and NKX2.5 
expression from HSV vector vββG4Nk induces the expression of other cardiac genes in mESC 
and differentiating EB, and increases the cardiogenic potential of mESC. It also highlights some 
of the difficulties in culturing and attempting to differentiate pluripotent stem cells into a specific 
cell lineage. We chose a combination of two genes that are known to be critical for embryonic 
heart development, engineered them into a single HSV vector that had been proven to efficiently 
transduce mESC, and attempted to make cardiomyocytes. While we obtained some promising 
results, we also discovered the pitfalls of intervening in the differentiation process. Pluripotent 
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stem cells can be maintained in culture nearly indefinitely, but the cells undergo an inherent drift 
over time, and these changes affect the way they differentiate. Parameters such as passage 
number, split rhythm, and undefined media components like serum all can alter the cardiac 
potential of PSC. The method used to initiate differentiation of stem cells also has a profound 
effect on the lineages produced. Using EB to differentiate mESC, as we did in these experiments, 
has both advantages and disadvantages. EB provide a three dimensional structure that mimics a 
developing embryo and fosters cell-cell interactions that are important for certain developmental 
programs, but the generation of cytokines and other factors within the EB can make experimental 
interpretation and reproducibility complicated. Lack of reproducibility between repeats of the 
same experiment was one of the biggest difficulties we encountered in this project. Moving 
forward, we better understand these complexities and some of the ways in which they can be 
controlled. 
 
 89 
5.0  POLYCISTRONIC JΔNI8 VECTORS FOR THE CARDIAC DIFFERENTIATION 
OF EMBRYONIC STEM CELLS 
5.1 INTRODUCTION 
Herpes simplex virus (HSV) is a double stranded DNA virus with a large (~152 kb) genome and 
a broad host cell range. HSV is readily rendered replication-incompetent by the deletion of 
essential immediate early genes, and its toxicity to host cells is mitigated through reduction or 
eradication of expression of other immediate-early viral proteins, particularly ICP0. Because its 
large genome contains repeated sequences and many genes that are not required for host cell 
transduction, extensive deletions can be made without significantly inhibiting its infectivity. 
These deletions allow substantial room for the insertion of large transgenes or polycistronic 
transgene cassettes, unlike other viral vectors including adeno-associated virus and lentivirus 
vectors that have a much smaller genome packaging capacity. Unlike typical lentiviral and 
retroviral vectors, HSV genomes do not integrate into the host cell genome, a feature that is 
crucial for clinical translation. HSV vectors can efficiently transduce embryonic stem cells, and 
expression of developmental genes in ESC from HSV vectors has been shown to produce 
lineage-related alterations in gene expression profiles (132). 
Red-mediated recombineering in bacteria was used to derive vGFP, vG4Nk, and vGTM 
from HSV vector JΔNI8GFP, a UL41-deleted version of JΔNI7GFP previously described by 
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Miyagawa et al. (169). JΔNI8GFP is deleted for the ICP0, ICP4, and ICP27 immediate early (α) 
genes, the entire internal repeat or joint region, the UL41 gene and the ICP47 promoter and start 
codon, and the VP-16 binding motifs in the ICP22 gene regulatory region to change its 
expression kinetics from that of an immediate early gene to that of an early (β) gene. The BAC 
elements, including a chloramphenicol-resistance gene (cmR) and β-galactosidase expression 
cassette, are located between loxP sites in the UL37-UL38 intergenic region (214), and the 
vector contains a hyperactive N/T double mutation in the gB gene to enhance viral entry into 
cells (215). An mCherry expression cassette driven by the ubiquitin C promoter is in the deleted 
ICP4 locus, and an eGFP expression cassette driven by the CAG promoter is in the LAT locus.  
JΔNI8GFP is a highly defective, high capacity, non-toxic HSV vector that is capable of 
robust transgene expression from the LAT locus not only in neuronal, but also in many non-
neuronal cell types, despite the absence of all IE gene expression. We engineered this backbone 
to express two different polycistronic cardiac cassettes from the LAT locus for cardiomyocyte 
differentiation/transdifferentiation. vG4Nk expresses GATA4, NKX2.5, and eGFP, separated by 
2A “ribosomal skipping” sequences (212), from a single CAG promoter. GATA4 and NKX2.5 
transgenes were chosen to enhance the cardiac differentiation of embryonic stem cells because 
they are both vital cardiac transcription factors that are spatiotemporally co-expressed in the 
precardiac mesoderm. GATA4 and NKX2.5 associate with one another to bind to the promoters 
of other cardiogenic genes, synergistically inducing their transcription (141), and loss of either 
gene function results in the absence of heart formation and early embryonic lethality (135). 
vGTM was initially conceived as a vector for the transdifferentiation of fibroblasts into 
cardiomyocytes. Like vG4Nk, it expresses cardiac transcription factors from a single CAG 
promoter as one continuous transcript with genes separated by 2A sequences to allow translation 
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of individual proteins. GATA4, TBX5, and MEF2C are cardiac-specific transcription factors that 
are vital for embryonic heart development. GATA4 has been shown to physically interact with 
both TBX5 (216) and MEF2C (217) to synergistically activate the transcription of other cardiac 
genes. Expression of the combination of these three transcription factors via retroviral 
transduction of fibroblasts facilitated the first reported success in achieving the in vitro 
transdifferentiation of a terminally differentiated cell type into cardiomyocytes (143). Soon after, 
it was reported that the same combination with the addition of Hand2 could reprogram 
fibroblasts in vitro with greater efficiency, and also could reprogram fibroblasts into 
cardiomyocytes in vivo (145). Yet another transdifferention cocktail including MEF2C, TBX5, 
and MYOCD has since been used to reprogram fibroblasts into cardiomyocyte-like cells in vitro 
(218). Qian et al. more recently reported the highly successful in vivo reprogramming of non-
myocytes into cardiomyocytes in the adult mouse heart following coronary artery ligation. 
Retroviruses expressing GATA4, TBX5, and MEF2C were injected directly into the heart, 
resulting in decreased infarct size and moderate improvements in cardiac function up to three 
months post MI (144). 
vG4Nk and vGTM each efficiently transduced mouse embryonic stem cells and robustly 
expressed GATA4 and NKX2.5 or GATA4, TBX5, and MEF2C proteins, respectively. 
Expression of these transgenes from vG4Nk and vGTM in mESC induced early but transient 
upregulation of endogenous cardiac genes in differentiating EB, yet produced an increased 
number of EB containing spontaneously contracting cells.  Our results clearly indicate that 
infection of a small number of stem cells with vG4Nk or vGTM has far reaching effects on the 
mESC differentiation program even when the virus genomes have been drastically diluted as the 
cells continue to rapidly divide over a period of 12 days. These experiments demonstrate that 
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mESC are responsive to gene induction by cardiac transcription factors delivered from JΔNI8-
derived vectors, and indicate that JΔNI8-based vectors can successfully alter the differentiation 
program of embryonic stem cells. 
5.2 MATERIALS AND METHODS 
5.2.1 Cells and culture conditions 
HSV vectors in which ICP4, ICP27, and ICP0 have been deleted were propagated on U2OS-
ICP4/27 cells (169), human osteosarcoma cells that contain both ICP4 and ICP27 coding 
sequences under control of their native promoters, taking advantage of the ICP0 
complementation properties of the U2OS cell line (219). These cells were cultured in DMEM 
(Corning) supplemented with 10% FBS (GIBCO), 100 U/ml penicillin (Cellgro), and 100 μg/ml 
streptomycin (Cellgro). U2OS-ICP4/27 cells were maintained under constant selection with 2 
μg/ml puromycin and 10 μg/ml blasticidin (Sigma). 
D3 mouse embryonic stem cells (a gift from T.E. Smithgall, University of Pittsburgh) 
were cultured in DMEM (Corning) supplemented with 15% FBS (GIBCO), 1% non-essential 
amino acids (GIBCO), 1 mM sodium pyruvate (GIBCO), 100 U/ml penicillin, 100 μg/mL 
streptomycin (Cellgro), 0.1 mM 2-mercaptoethanol (GIBCO), and 1000 U/ml mouse LIF 
(Millipore) on 10 cm dishes coated with 0.2% gelatin (Sigma). Media was exchanged daily and 
cells were passaged with trypsin every 2-3 d to maintain a state of self-renewal and minimize 
spontaneous differentiation. 
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5.2.2 G4NkeGFP cassette construction 
The pG4NkmCh plasmid described above was modified to contain eGFP instead of mCherry as a 
reporter gene. The eGFP coding sequence was PCR amplified from the commercially available 
plasmid pEGFP-N1 (Clontech) using primers F/Xho-E2A-eGFP and R/eGFP-Pme (Table 4), 
giving a 719 bp fragment that begins with an XhoI restriction site, then the E2A sequence, the 
eGFP coding sequence, and ends with a PmeI restriction site (XhoI-E2A-eGFP-PmeI). The 
purified PCR product was then digested with XhoI and PmeI. Plasmid pG4NkmCh was digested 
with XhoI and PmeI, the 7.2 kb backbone fragment purified from an agarose gel, and then the 
PCR product was ligated into the plasmid to create pG4NkeGFP. 
5.2.3 GTMeGFP cassette construction 
cDNAs for human MEF2C and TBX5 were obtained from Open Biosystems and sequenced for 
verification (Genewiz). The GTMeGFP cassette was built in two steps. First human GATA4, 
TBX5, and mCherry cDNAs were PCR amplified with primers to add convenient restriction sites 
and 2A sequences and ligated into pcDNA-CAGp (described in section 4.3.2) resulting in 
plasmid pGTMmCh, and then mCherry was replaced with eGFP. Briefly, GATA4 was amplified 
with primers F/EcoRI-GATA4 and R/GATA4-T2A and Tbx5 was amplified with primers 
F/T2A-Tbx5 and R/Tbx5-PspXI. The resulting two PCR products were then amplified together 
with F/EcoRI-GATA4 and R/Tbx5-PspXI to produce a fragment that begins with an EcoRI 
restriction site, then a start codon, the GATA4 coding sequence, the T2A sequence, the TBX5 
coding sequence, and ending with a PspXI restriction site (EcoRI-GATA4-T2A-Tbx5-PspXI) all 
in the same ORF. Plasmid pcDNA-CAGp and fragment EcoRI-GATA4-T2A-Tbx5-PspXI were 
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each cut with EcoRI and PspXI and the fragment was ligated into the plasmid backbone to give 
rise to plasmid pGT. Next MEF2C was PCR amplified with primers F/PspXI-E2A-Mef2c and 
R/Mef2c-F2A and mCherry was PCR amplified from pG4NkmCh with primers F/F2A and 
R/mCherry-Pme. The resulting two PCR products were amplified together with primers 
F/PspXI-E2A-Mef2c and R/mCherry-Pme giving a fragment beginning with a PspXI restriction 
site, the E2A sequence, Mef2c coding sequence, the F2A sequence, mCherry coding sequence, 
and ending in a PmeI restriction site (PspXI-E2A-Mef2c-F2A-mCherry-PmeI). This fragment 
and plasmid pGT were digested with PspXI and PmeI and the mCherry fragment was ligated into 
the plasmid, giving rise to plasmid pGTMmCh, with GATA4, TBX5, MEF2C, and mCherry all in 
one continuous ORF. Sequences were obtained for all parts of the cassette to verify that no errors 
occurred during PCR amplification (Genewiz). Next mCherry was replaced in pGTMmCh with 
eGFP. The eGFP coding sequence was PCR amplified from the commercially available plasmid 
pEGFP-N1 (Life Technologies) using primers F/F2A-eGFP and R/eGFP-Pme to produce a 
fragment containing part of the F2A sequence, the eGFP coding sequence, and a PmeI restriction 
site. Next the plasmid containing the MEF2C cDNA (Open Biosystems) was PCR amplified with 
primers F/PspXI-E2A-Mef2c and R/Mef2c-F2A to produce a fragment containing a PspXI 
restriction site, the E2A sequence, the MEF2C coding sequence, and part of the F2A sequence. 
The previous two fragments were PCR amplified together with primers F/PspXI-E2A-Mef2c and 
R/eGFP-Pme to produce 2.2 kb fragment PspXI-E2A-Mef2c-F2A-eGFP-PmeI. Both this 
fragment and plasmid pGTMmCh were digested with PspXI and PmeI, and the PspXI-E2A-
Mef2c-F2A-eGFP fragment was ligated into the backbone, creating plasmid pGTMeGFP with 
GATA4, TBX5, MEF2C, and eGFP separated by 2A sequences and all in one continuous ORF. 
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Sequences were obtained for all parts of the cassette to verify that no errors occurred during PCR 
amplification (Genewiz). 
 96 
Table 6. Primer sequences for construction of GTMmCh and GTMeGFP cassettes 
 
 
F/Xho-E2A-
eGFP 
CTGAGCCTCGAGGGTCAATGTACTAACTACGCTTTGTTGAAACTCGCTGGC 
GATGTTGAAAGTAACCCCGGTCCTatggtgagcaagggcgaggagctg 
R/eGFP-Pme CTGTGGGTTTAAACctatcacttgtacagctcgtccatg 
F/EcoRI-GATA4 ccacaGAATTCGTAATAGGATAGCGACatgtatcagagcttggccatg 
R/GATA4-T2A CCTCGACGTCACCGCATGTTAGCAGACTTCCTCTGCCCTCTCCGGAGCCcgc 
agtgattatgtccccgtgac 
F/T2A-Tbx5 GAAGTCTGCTAACATGCGGTGACGTCGAGGAGAATCCTGGCCCAatggccgacg 
cagacgagggctttg 
R/Tbx5-PspXI CTGTAGACTCGAGCgctattgtcgctccactctgg 
F/PspXI-E2A-
Mef2c 
CTGAGCGCTCGAGTCGGTCAATGTACTAACTACGCTTTGTTGAAACTCGCTGGC 
GATGTTGAAAGTAACCCCGGTCCTatggggagaaaaaagattcagattac 
R/Mef2c-F2A CCACGTCTCCCGCCAACTTGAGAAGGTCAAAATTCAAAGTCTGTTTCACgccagaa 
ccttcagaaagtcgcatg 
F/F2A GAGACGTGGAGTCCAACCCAGGGCCC 
R/mCherry-Pme CTGTGGGTTTAAACctatcatgggtccttgtacagctcg 
R/Mef2c-F2A CCACGTCTCCCGCCAACTTGAGAAGGTCAAAATTCAAAGTCTGTTTCACgccagaa 
ccttcagaaagtcgcatg 
F/F2A-eGFP ACCTTCTCAAGTTGGCGGGAGACGTGGAGTCCAACCCAGGGCCCatggtgagcaagg 
gcgaggagctg 
 
 
Underlined sequences are restriction sites, green designates start codons, blue designates 2A sequences 
(italics for partial 2A), and red designates stop codons. 
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5.2.4 JΔNI8 vector engineering 
Red-mediated recombineering in bacteria (220) was used to create the described HSV-BAC 
constructs. All HSV-BAC constructs described are derived from the JΔNI8GFP HSV-BAC, 
generated by Y. Miyagawa (169). BAC engineering was performed with pRed/ET (Gene 
Bridges) and pBAD-I-SceI plasmid (from N. Osterrieder, Free University of Berlin, Germany) 
with E. coli strain GS1783 (from G. Smith, Northwestern University, Chicago, IL) as described 
(221), see Figure 22. First mCherry was deleted from the ICP4 locus of JΔNI8GFP BAC. The 
kanamycin resistance gene and I-SceI sequences flanked by sequences surrounding mCherry in 
the ICP4 locus of JΔNI8GFP BAC were PCR amplified from plasmid pBAD-I-SceI with primers 
EpKAN-del-mCherry-f1 and EpKAN-del-mCherry-r. The resulting fragment was then amplified 
with EpKAN-del-mCherry-f2 and EpKAN-del-mCherry-r for Red-mediated recombination into 
the ICP4 locus to delete mCherry and insert the kanamycin resistance gene, which was then 
selected for and removed as previously described (220, 221). The resulting HSV-BAC was 
termed JΔNI8GFPΔcherry. Next the kanamycin resistance cassette (kanR) and I-SceI sites were 
introduced into the BamHI site of the GATA4 coding sequence in plasmid pG4NkeGFP and into 
the Asp718 site of the MEF2C site of pGTMeGFP. For pG4NkeGFP, plasmid pBAD-I-SceI was 
PCR amplified with primers F/Kan-GATA4 and R/Kan-GATA4. This PCR fragment was 
digested with BamHI and cloned into the BamHI site in pG4NkeGFP. For pGTMeGFP, plasmid 
pBAD-I-SceI was PCR amplified with primers F/Kan-Mef2c and R/Kan-Mef2c. This PCR 
fragment was digested with Asp718 and cloned into the Asp718 site in pGTMeGFP. Each gene 
cassette containing kanR was recombined into the LAT locus of JΔNI8GFPΔcherry-BAC, 
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followed by kanamycin selection and then removal of the kanamycin cassette from GATA4 and 
MEF2C coding sequences to create HSV-BACs JΔNI8G4NkeGFP and JΔNI8GTMeGFP.  
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Figure 22. Example schematic of Red/ET recombineering steps 
A kanR cassette consisting of an I-SceI restriction site, kanamycin resistance gene, and 50 bp direct repeat 
of the target sequence was inserted into the GATA4 gene in the G4NkeGFP LAT-targeting construct. In 
step 1, the multigene cassette was electroporated into E. coli strain GS1783 that was transformed with the 
JΔNI8GFPΔcherry BAC and selected for cmR. GS1783 contains a temperature inducible (TS) promoter 
driving expression of Red recombinase and an arabinose inducible (ArabS) promoter driving expression of 
restriction enzyme I-SceI. Production of Red recombinase was induced by culturing the cells at 42°C, 
allowing the G4NkeGFP cassette to recombine into the LAT locus via homology with the CAG promoter 
and the eGFP coding sequence present in JΔNI8GFPΔcherry BAC. Recombinants were selected for 
kanR/cmR and confirmed by PCR and FIGE. In step 2, the kanR cassette is excised. Arabinose was added 
to the culture to induce the production of I-SceI, which then cut the BAC DNA immediately to the left of 
the kanR gene. The cells were cultured at 42°C to produce Red recombinase and thereby promote 
recombination between the direct repeats inside the GATA4 gene, seamlessly removing kanR and leaving 
the GATA4 coding sequence intact. Recombinants were screened for kanS/cmR and confirmed by PCR and 
FIGE. 
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Table 7. Primer sequences for BAC recombineering 
 
  
EpKAN-del-mCherry-f1 GGCGGGTGCGCCGTGCTCTGTTGGTTTCACCTGTGGCAGCCCGGGCC 
CCCCGCGGaggatgacgacgataagtagggata 
EpKAN-del-mCherry-r CCGCGGGGGGCCCGGGCTGCCACAGGTGAAACCAACAGAGCACGGC 
GCACcaaccaattaaccaattctgattag 
EpKAN-del-mCherry-f2 CTTGGGGCGGTCCCGCCCGCCGGCCAATGGGGGGGCGGCAAGGCGG 
GCGGGTGCGCCGTGCTCTGTTGGT 
F/Kan-GATA4 GAGGGGATCCAAACCAGAAAACGGAAGCCCAAGAACCTGAATAAATCT 
AAGACAAGGATGACGATAAGTAGGGATA 
R/Kan-GATA4 CACAGGATCCCAACCAATTAACCAATTCTGATTAG  
F/Kan-Mef2c GAGGGGTACCGAGTACTCTCTGAGTAGTGCAGACCTGTCATCTCTGTCT
GGGTTAGGATGACGACGATAAGTAGGGATA 
R/Kan-Mef2c CACAGGTACCCAACCAATTAACCAATTCTGATTAG 
 
 
Underlined sequences represent restriction sites added with primers. 
 
 
 
JΔNI8 BAC DNA constructs were confirmed by PCR analysis, FIGE analysis of 
restriction enzyme digests, and targeted DNA sequencing. JΔNI8GFPΔcherry, 
JΔNI8G4NkeGFP, and JΔNI8GTMeGFP BACs were converted into infectious viruses (vGFP, 
vG4Nk, and vGTM, respectively) by transfection into U2OS-ICP4/27 cells. 4 μg BAC DNA in 
500 μl OptiMEM (Invitrogen) was incubated with 1 μl Lipofectamine Plus Reagent (Invitrogen) 
for 5 min at room temperature, then 6.25 μl Lipofectamine LTX (Invitrogen) was added and the 
mixture incubated at room temperature for 30 min before being added to the cells. The cells in 
transfection mixture were incubated at 37°C for 6 h, then the media was replaced with serum free 
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DMEM and the cells were cultured overnight at 37°C.  The cells were transferred to 33°C and 
virus growth was monitored until complete CPE was observed. Supernatant virus was titered and 
the viruses were amplified through infection of sequentially larger cultures at an MOI of 0.001 
pfu/cell. For large scale production, U2OS-ICP4/27 cells were plated in the desired number of 
T150 flasks and confluent monolayer cells were infected at an MOI of 0.0001 pfu/cell in 10 ml 
serum free DMEM (Corning) per flask with occasional gentle agitation for 2 h at 37°C. After 2h, 
10 ml serum free DMEM was added to each flask, and the infected cells were incubated at 33°C 
to allow for maximum virus survival without cell overgrowth until the entire flask reached CPE, 
typically 7-10 days post infection. The media was then collected and the dead cells were spun 
out in a table top centrifuge at 3000 rpm for 10 min at 4°C. The supernatant containing the virus 
was filtered through a 0.8 μm then a 0.45 μm Versapor membrane (PALL Corporation), and then 
concentrated by multiple cycles of high-speed centrifugation at 19,500 rpm for 45 min each 
cycle. All of the supernatant was spun down into 2 – 4 tubes, and the resulting viral pellets were 
each gently resuspended in 200 μl PBS with 10% glycerol by slow shaking at 4°C for 24-48 h. 
The resulting concentrated virus was divided into 5-20 μl aliquots and stored at -80°C. 
5.2.5 Genome copy titer of JΔNI8 vectors 
Genome copy titer measurements were performed on 5 μl aliquots of all JΔNI8-based vectors. 
Viral DNA was extracted with the DNeasy Blood & Tissue Kit (Qiagen). Genome copy titers 
were determined by qPCR for the glycoprotein D (gD) (222) with a TaqMan primer and probe 
set (Invitrogen) using conditions described above. Cellular 18S ribosomal DNA levels were 
measured with TaqMan Ribosomal RNA control reagents (Invitrogen) and were used to 
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normalize viral DNA amounts. Absolute genome copy titers were calculated as previously 
described (222-224). 
5.2.6 Western blot analysis 
GATA4, NKX2.5, TBX5, and MEF2C expression from both pG4NkeGFP and pGTMeGFP were 
confirmed by transfecting U2OS-ICP4/27 cells with the plasmids using Lipofectamine LTX 
(Invitrogen) according to the manufacturer’s protocol and collecting proteins from the cells 48 h 
post transfection. GATA4, NKX2.5, TBX5, and MEF2C expression from vG4Nk and vGTM 
was confirmed by infecting U2OS-ICP4/27 cells, non-complementing U2OS cells, and D3 
mouse embryonic stem cells and collecting proteins 24 hpi. Cell lysates were collected in RIPA 
lysis buffer supplemented with protease inhibitors (Roche). Proteins were separated on a 10% 
polyacrylamide gel and transferred by semi-dry transfer onto PVDF membranes. The membranes 
were washed in TBS and blocked for 1 h at room temperature in TBS-T (20 mM Tris, 0.5 M 
NaCl [pH 7.5] plus 0.5% Tween 20) supplemented with 10% nonfat dry milk. Primary 
antibodies were diluted in blocking buffer. The diluted antibodies were reacted with the blocked 
PVDF overnight at 4°C, washed 3 times for 10 min each in TBS-T, and reacted with horseradish 
peroxidase-conjugated secondary antibodies diluted in blocking buffer for 1 h at room 
temperature. The bound Igs were revealed by enhanced chemiluminescence (Thermo Scientific). 
Antibody information can be found in Table 1. 
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5.2.7 Embryoid body assay 
D3 mouse embryonic stem cells were infected in suspension with vGFP, vG4Nk, vGTM, or 
mock infected in a small volume in Eppendorf tubes at 37°C with continuous rotation for 1-2 h. 
Infected cells were diluted in mESC media without LIF at a concentration of 4x104 cells/ml. 20 
μl drops of cells were pipetted onto the lid of a petri dish, and the lid was inverted over the dish 
that contained 30 ml sterile water to prevent the drops from evaporating. The cells were 
incubated at 37°C with 5% CO2 and allowed to aggregate to form embryoid bodies (EB) and 
differentiate for two days in hanging drops. After 48 h in hanging drops, the EB were pipetted 
one per well into 48 well plates, each well containing 500 μl mESC media without LIF. EB were 
observed daily for the appearance of spontaneously contracting cells, and the number of wells 
containing these cells was recorded each day. 
5.2.8 Cytosine β-D-arabinofuranoside (Ara-C) to inhibit cell division 
Cytosine β-D-arabinofuranoside (Sigma) was used to inhibit mESC division following 
transduction with HSV vectors. mESC were treated with 0.3uM Ara-C for 48 hpi after the onset 
of differentiation in EB. Ara-C was diluted upon plating EB and then completely washed out 24 
h later.  
5.2.9 RNA extraction and quantitative RT-PCR analysis 
Total RNA was extracted from D3 mES cell lines and embryoid bodies using Qiagen RNeasy 
Plus mini kit (Qiagen) according to the manufacturer’s protocol.  
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Reverse transcription was performed on 1-2 μg RNA in 20 μl final volume using random 
decamers as first strand primers with Ambion’s RETROscript Kit (Ambion), and the resulting 
cDNA was diluted 1:10 for quantitative RT-PCR analysis. 
Primers were obtained from Invitrogen. Primer sequences and references for qPCR are 
listed in Table 1. qPCR was performed using LightCycler SYBRgreen Master Mix (Roche) or 
TaqMan Gene Expression Assays (Invitrogen) and a Step One Plus Real-Time PCR System 
(Applied Biosystems). Cycling conditions were 95°C for 10 min followed by 40 cycles of 95°C 
for 15 sec and then 60°C for 1 min. Each cDNA was analyzed in triplicate, and the results for the 
three wells were averaged. Threshold cycle (Ct) values were used to calculate changes in gene 
expression using the 2-ΔΔCt method (195). Expression levels were normalized to HPRT mRNA 
for SYBRgreen or 18S ribosomal RNA levels for TaqMan, and expressed relative to uninfected 
D3 mESC. 
5.3 RESULTS 
5.3.1 Assembly and validation of differentiation and trans-differentiation cassettes 
Polycistronic cassettes G4NkeGFP and GTMeGFP were assembled in plasmid pcDNA-CAGp 
(section 4.3.2) to co-express GATA4, NKX2.5, and eGFP or GATA4, TBX5, MEF2C, and eGFP 
respectively (Figure 23A and Methods sections 5.3.2 and 5.3.3). Gene expression from each 
cassette is driven by a single CAG promoter, and genes are separated by 2A “ribosomal 
skipping” sequences (212) to allow for individual translation of each transgene.  
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The mCherry reporter gene in pG4NkmCh (Chapter 4, Figure 9) was replaced with an 
eGFP gene to allow for brighter fluorescence in transfected or infected cells. The reporter gene 
switch was verified by transfecting the constructs pG4NkmCh and pG4NkeGFP into Vero cells 
and observation of eGFP expression in the pG4NkeGFP-transfected cells (Figure 23B, upper).  
Plasmid pGTMeGFP was constructed by first creating pGTMmCh through PCR 
amplification of human GATA4, TBX5, and MEF2C cDNAs with 2A extensions and cloning 
them into pcDNA-CAGp with mCherry as the final gene in the cassette (described in 5.3.3). 
Expression of GATA4, TBX5, MEF2C, and mCherry from pGTMmCh was verified by 
transfecting the plasmid into U2OS-ICP4 cells, collecting cells lysates 48 h post transfection, and 
Western blotting with antibodies against the transgene products (Figure 23C). mCherry was 
replaced by eGFP using the same template, primers, and cloning strategy as for pG4NkeGFP to 
create pGTMeGFP, and the resulting plasmid was transfected into Vero cells to confirm the 
reporter gene switch (Figure 23B, lower).  
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Figure 23. Cassette schematics and verification of gene expression from pG4NkeGFP and 
pGTMeGFP 
(A) Trangene cassettes for the expression of eGFP alone, GATA4, NKX2.5, and eGFP, and GATA4, TBX5, 
MEF2C, and eGFP, each from a single CAG promoter. (B) Fluorescence microscopy pictures of Vero 
cells transfected with parental plasmids pG4NkmCh or pGTMmCh and imaged for mCherry expression 
or with derivatives pG4NkeGFP or pGTMeGFP and imaged for GFP expression 48 h post transfection. 
(C) Western blots of lysates collected 48 h post transfection from U2OS-ICP4 cells transfected with 
various expression plasmids: untransfected cells (lane 1), pcGWmCherry (lane 2), pH41G4NkmCh (lane 
3), and 3 clones of pGTMmCh (lanes 4-6). 
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5.3.2 Deletion of mCherry from JΔNI8GFP BAC 
HSV vector JΔNI8GFP was constructed in our lab by Yoshitaka Miyagawa as a UL41-deleted 
derivative of JΔNI7GFP described in reference (169). To allow for the use of red fluorescent 
secondary antibodies for immunofluorescence imaging and flow cytometry of transduced cells, 
mCherry was deleted from the ICP4 locus of JΔNI8GFP BAC so that the resulting HSV vector 
would contain a single fluorescent reporter gene. Engineering of BAC DNA was performed by 
Red-mediated recombination in E. coli strain GS1783. This bacterial strain contains a 
temperature-inducible expression cassette for the phage λ Red proteins Exo, Beta and Gam, and 
an arabinose-inducible gene for the rare-cutting homing endonuclease I-SceI in its chromosomal 
DNA (221). An mCherry deletion construct consisting of the kanamycin resistance gene (kanR) 
flanked by homology arms to the ICP4 region surrounding the mCherry cassette in JΔNI8GFP 
BAC was created by PCR amplification. The construct was electroporated into bacteria 
containing JΔNI8GFP BAC, and BAC recombinants were selected on 
chloramphenicol/kanamycin-containing agar plates. Proper recombinants were identified using 
PCR with primers to amplify the region surrounding the ICP4 locus. The primers were designed 
to amplify a 2515 bp product containing the mCherry coding sequence in the parent JΔNI8GFP 
BAC. Upon replacement of the mCherry gene with the kanR gene, these primers would yield a 
product of 1300 bp (Figure 24A, left). Clones #2 and #6 produced a product of the expected size 
(Figure 24A, right). These products were verified by sequencing. Large BAC DNA preps were 
produced for the two recombinants and the parental DNA for comparison. The DNAs were 
digested overnight with BsrGI and the resulting fragments were resolved by field inversion gel 
 108 
electrophoresis (FIGE). Successful recombination resulted in the elimination of the BsrGI site 
inside the mCherry coding sequence, causing a shift of the 3.9 kb and 16.5 kb fragments of the 
parental BAC DNA into a single 19.2 kb fragment (Figure 24B); no other changes from the 
parental BAC DNA were observed. The recombinants were called JΔNI8GFPΔcherryKanR 
BAC.   
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Figure 24. Verification of mCherry deletion/KanR insertion into JΔNI8GFP BAC 
(A) PCR amplification of the region surrounding the mCherry deletion/KanR insertion. The left panel 
shows a diagram of the area surrounding the ICP4 region before and after recombination. Locations of 
PCR primers are marked by small black arrows. The right panel shows the results of PCR performed on 5 
different JΔNI8GFPΔcherryKanR BAC clones and parent JΔNI8GFP. (B) FIGE analysis of BsrGI-
digested JΔNI8GFP and 2 clones of JΔNI8GFPΔcherryKanR BAC DNA. The left panel shows the FIGE 
gel with arrows marking the fragments that change, before (orange) and after (green) recombination. The 
right panel shows a schematic of the area of recombination and the sizes of the expected fragments upon 
BsrGI digestion.  
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The kanR gene was excised from the ICP4 locus of JΔNI8GFPΔcherryKanR BAC DNA 
by arabinose activation of the I-SceI promoter and heat activation (42°C) of the recombinase 
promoter of the GS1783 host cells. Kanamycin-sensitive/chloramphenicolR colonies were 
identified and PCR was used to amplify the region surrounding the anticipated kanR deletion in 
both JΔNI8GFPΔcherryKanR clones. Successful recombination produced a 189 bp product, 
compared to the 1300 bp kanR-containing product resulting from PCR with the same primers on 
JΔNI8GFPΔcherryKanR DNA (Figure 25A). Several successful recombinants were verified 
through sequencing. DNA from these recombinants and the parental BAC were digested 
overnight with EcoRI and the digests were analyzed by FIGE. Deletion of kanR resulted in a shift 
of the 21.5 kb fragment to 20.4 kb (Figure 25B). All three of the recombinants that were 
analyzed showed the correct digestion pattern, indicating that JΔNI8GFPΔcherry BAC was 
successfully created. 
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Figure 25. Verification of KanR deletion from JΔNI8GFPΔcherry BAC 
(A) PCR amplification of the region surrounding the kanR deletion. The left panel shows a diagram of the 
area surrounding the ICP4 region before and after recombination. Locations of PCR primers are marked 
by small black arrows. The right panel shows the results of PCR performed on 5 different 
JΔNI8GFPΔcherry BAC clones and both parent BACs JΔNI8GFPΔcherryKanR #2 and #6. (B) FIGE 
analysis of EcoRI-digested JΔNI8GFPΔcherryKanR and 3 clones of JΔNI8GFPΔcherry BAC DNA. The 
left panel shows the FIGE gel with arrows marking the fragments that change, before (orange) and after 
(green) recombination. The right panel shows a schematic of the area of recombination and the sizes of 
the expected fragments upon EcoRI digestion. 
 
 
5.3.3 Insertion of a 2A-linked GATA4-NKX2.5 cassette into JΔNI8GFPΔcherry BAC 
A unique BamHI site inside the coding sequence of GATA4 in the plasmid pG4NkeGFP was 
used to insert the kanR/I-SceI selection cassette prior to recombination of G4NkeGFP into vGFP. 
KanR was PCR amplified from pBAD-I-SceI with primers to add BamHI sites and a 50 bp direct 
repeat of GATA4 coding sequence (Figure 26A). Both the resulting PCR product and 
pG4NkeGFP were digested with BamHI, the PCR product was ligated into the backbone. Insert 
orientation was checked with diagnostic restriction digests. Several clones with the correct 
orientation (kanR between a 50 bp direct repeat of GATA4 sequences) were identified and 
sequenced. One pG4(kanR)NkeGFP clone with the correct sequence was digested with PmeI and 
SnaBI to produce a 5597 bp fragment for recombination into the LAT locus of 
JΔNI8GFPΔcherry BAC DNA (Figure 26B). This fragment had separate regions of homology 
with the CAG promoter and the eGFP coding sequence present in the LAT locus of vGFP to 
direct homologous recombination upon electroporation into bacteria containing 
JΔNI8GFPΔcherry BAC DNA (Figure 26C). CmR/kanR colonies were selected and the 5’ and 3’ 
recombination regions were PCR amplified and sequenced to verify that no sequence changes 
had occurred.  
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Figure 26. Scheme for introducing kanR into pG4NkeGFP and digestion for recombination 
(A) Diagram and gel of PCR product for insertion of kanR into a BamHI site inside GATA4 and BamHI 
digest of pG4NkeGFP. (B) Schematic of G4(kanR)NkeGFP and digest with PmeI and SnaBI for 
recombination into JΔNI8GFPΔcherry BAC DNA. (C) Homologous sequences (CAG, eGFP) between 
the G4(kanR)NkeGFP cassette and the LAT locus of JΔNI8GFPΔcherry BAC DNA for recombination.  
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FIGE analysis of MfeI-digested recombinant JΔNI8G4(kanR)NkeGFP and parental 
JΔNI8GFPΔcherry BAC DNA confirmed that the G4(kanR)NkeGFP was successfully 
recombined into JΔNI8GFPΔcherry BAC DNA in the three clones examined. A 14.9 kb MfeI 
fragment containing the eGFP expression cassette in the parent BAC increased in size to 17.6 kb 
following recombination, consistent with acquisition of the GATA4(kanR)Nkx2.5 sequence 
(Figure 27).   
To generate the final JΔNI8G4NkeGFP BAC construct, the kanR gene was removed as 
described above using arabinose-induced I-SceI expression and heat activation of the Red 
proteins in the BAC-containing GS1783 bacteria. KanR excision was first verified by PCR using 
primers to both sides of the kanR gene. A 2342 bp product was amplified from the parental BAC. 
All 5 recombinants tested yielded a 1298 bp product (Figure 28A), consistent with clean deletion 
of the kanR gene that was confirmed by DNA sequencing. FIGE analysis of MfeI digested BAC 
DNA before and after recombination also verified the successful excision of kanR. The 17.6 kb 
MfeI fragment that contained kanR was reduced to 16.5 kb following recombination (Figure 
28B). All four clones analyzed showed the expected change, completing the engineering 
JΔNI8G4NkeGFP BAC. 
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Figure 27. FIGE analysis of MfeI-digested candidate JΔNI8G4(kanR)NkeGFP BAC isolates 
The left panel shows the FIGE gel with arrows marking the fragments that change, before (orange) and 
after (green) recombination. The right panel shows a schematic of the area of recombination and the sizes 
of the expected fragments upon MfeI digestion. 
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Figure 28. Removal of kanR from JΔNI8G4(kanR)NkeGFP 
(A) PCR analysis of BAC DNA from 5 kan-sensitive bacterial colonies resulting from Red recombination 
to delete the kan gene from JΔNI8G4(kanR)NkeGFP BAC DNA. The left panel shows a diagram of the 
transgene cassette in the LAT locus before and after recombination. The small black arrows indicate the 
location of the primers surrounding the deletion with the expected product length indicated underneath.  
The right panel shows the PCR products. (B) FIGE analysis of MfeI-digested BAC DNA. The right panel 
shows a diagram of the MfeI fragment that changes length upon recombination. The orange arrow on the 
FIGE gel in the left panel shows the fragment length before and the green arrow shows the fragment 
length after kanR excision.  
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5.3.4 Construction of a JΔNI8GFPΔcherry BAC derivative for single promoter 
expression of GATA4, TBX5, and MEF2C  
Procedures similar to those described in the previous section were used to generate a BAC 
construct for HSV-mediated production of the transdifferentiation cocktail GATA4, TBX5 and 
MEF2C along with eGFP from a single transcript. The strategy was to replace the NKX2.5 gene 
of JΔNI8G4NkeGFP BAC with 2A-linked TBX5 and MEF2C cDNAs using the GATA4 and 
eGFP portions of plasmid pGTMeGFP described in section 5.4.1 as homology arms for Red-
mediated recombination.  
In the first step, a unique Asp718 (KpnI) site inside the MEF2C coding sequence of 
pGTMeGFP was used to insert the kanR/I-SceI selection cassette. The kanR/I-SceI cassette was 
PCR amplified from pBAD-I-SceI with primers to add Asp718 sites and a 50 bp direct repeat of 
MEF2C coding sequence (Figure 29A). The Asp718-digested PCR product was cloned into the 
Asp718 site of pGTMeGFP; diagnostic restriction digests were used to identify the desired 
orientation of the insert and several candidates were confirmed by DNA sequencing. One of 
these [pGTM(kanR)eGFP] was digested with PmeI and BamHI to produce a 5328 bp fragment 
for homology-directed recombination with JΔNI8G4NkeGFP BAC DNA (Figure 29B). The 
fragment was electroporated into bacteria containing JΔNI8G4NkeGFP BAC DNA and BAC 
recombinants were identified by selection for chloramphenicol and kanamycin resistance. 
Candidate BACs were isolated and confirmed by PCR and sequencing through the 5’ and 3’ 
recombination sites (data not shown) as well as by FIGE analysis of MfeI-digested BAC DNA  
[Figure 30, JΔNI8GTM(kanR)eGFP #1, 4 and 5]. 
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Figure 29. Scheme for introducing kanR into pGTMeGFP and digestion for recombination 
(A) Diagram and gel of PCR product for insertion of kanR into KpnI/Asp718 site inside MEF2C and KpnI 
and Asp718 digests of pGTMeGFP. (B) Homologous sequences between GTM(kanR)eGFP cassette and 
G4NkeGFP cassette in the LAT locus of JΔNI8G4NkeGFP BAC DNA for recombination. 
 
 
 
 
The final product, JΔNI8GTMeGFP BAC, was generated by excision of the kanR gene 
from JΔNI8GTM(kanR)eGFP BAC DNA, essentially as described in the previous section. KanR 
excision was verified by PCR (Figure 31A), FIGE analysis (Figure 31B), and DNA sequencing. 
The structures of the completed JΔNI8G4NkeGFP and JΔNI8GTMeGFP BAC constructs are 
illustrated in Figure 32. 
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Figure 30. MfeI digest and FIGE analysis of JΔNI8GTM(kanR)eGFP 
The left panel shows the FIGE gel with arrows marking the fragments that change, before (orange) and 
after (green) recombination. The right panel shows a schematic of the area of recombination and the sizes 
of the expected fragments upon MfeI digestion. 
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Figure 31. Removal of kanR from JΔNI8GTM(kanR)eGFP BAC DNA 
(A) PCR analysis of 3 clones selected after kanR excision from JΔNI8GTM(kanR)eGFP BAC DNA. The 
left panel shows a diagram of the transgene cassette in the LAT locus before and after recombination. The 
small black arrows indicate the location of the primers surrounding the deletion with the expected product 
lengths shown underneath.  The right panel shows the PCR products. (B) FIGE analysis of MfeI-digested 
BAC DNA. The right panel shows a diagram of the MfeI fragment that changes length upon 
recombination. The orange arrow on the FIGE gel in the left panel shows the relevant fragment length 
before and the green arrow shows the fragment length after kanR excision. 
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Figure 32. Structure of JΔNI8GFPΔcherry BAC and transgene expression cassettes engineered into 
the LAT locus 
The HSV vector JΔNI8GFP genome is shown schematically with genes labeled at the approximate 
location in the vector (not to scale). Deletions are depicted in black and the single IE to E gene promoter 
substitution (β) in yellow (169). Transgenes are colored and labeled. The transgene cassettes shown 
below the vector diagram are located within the LAT 2-kb intron region between LAT elements LAT P2 
and CTRL2. The relative position of LAT insulator CTRL1 is also indicated.  
 
 
 
5.3.5 Characterization of vectors JΔNI8G4NkeGFP and JΔNI8GTMeGFP 
JΔNI8GFPΔcherry, JΔNI8G4NkeGFP, and JΔNI8GTMeGFP BAC DNAs were converted to 
infectious viruses (vGFP, vG4Nk, and vGTM, respectively) by transfection into ICP4- and 
ICP27-complementing U2OS cells (U2OS-ICP4/27, (169)) that endogenously complement the 
ICP0 deletion (225). The success of the mCherry deletion was visualized by fluorescence 
microscopy. The parent vector JΔNI8GFP expressed both eGFP and mCherry upon transfection 
into U2OS-ICP4/27 cells while the mCherry-deleted JΔNI8GFPΔcherry (vGFP) expressed only 
 122 
eGFP (Figure 33A). Vector production was scaled up to 10 – 20 T150 flasks of cells per vector. 
Following CPE, the viruses were harvested and concentrated by centrifugation to produce high-
titer stocks. Plaque assays and qPCR were used to determine the plaque forming unit (pfu) and 
genome copy (gc) titers of all three vectors (Figure 33B). Expression of eGFP in non-
complementing U2OS cells infected with each virus stock at 1 pfu/cell was readily detectable 
(Figure 33C). 
 123 
 
 
 
Figure 33. Fluorescent marker expression and titers of JΔNI8 vectors 
(A) JΔNI8eGFP and JΔNI8eGFPΔcherry BAC DNA were transfected into U2OS-ICP4/27 cells. Pictures 
were taken 5 d post transfection. (B) Genome copy (gc) and plaque forming unit (pfu) titers of JΔNI8 
vectors. (C) eGFP expression 1 dpi in U2OS cells infected with vGFP, vG4Nk, or vGTM at 1 pfu/cell. 
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To verify that mESC transduced with vectors vG4Nk and vGTM expressed GATA4 and 
NKX2.5 or GATA4, TBX5, and MEF2C, respectively, mESC were infected with 1 pfu/cell of 
each vector. Mock-infected and vGFP-infected mESC were included as controls. Cell lysates 
were collected 24 hpi and separated by SDS-PAGE. Western blotting demonstrated that mESC 
infected with vG4Nk robustly expressed GATA4 and NKX2.5 proteins, while mock- and vGFP-
infected mESC did not (Figure 34A). Similarly, mESC infected with vGTM robustly expressed 
GATA4, TBX5, and MEF2C proteins, while mock- and vGFP-infected mESC did not (Figure 
34B). 
 
 
 
 
 
 
Figure 34. Transgenic protein expression from vG4Nk and vGTM 
mESC were infected with 1 pfu/cell in suspension and proteins collected for Western blots 24 hpi. (A) 
Western blots for GATA4, NKX2.5, and beta tubulin. Lane 1, mock-infected mESC; lane 2, vGFP-
infected mESC; lane 3, vG4Nk-infected mESC. (B) Western blots for GATA4, TBX5, MEF2C, and beta 
tubulin. Lane 1, mock-infected mESC; lane 2, vGFP-infected mESC; lane 4, vGTM-infected mESC. 
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5.3.6 Transduction of mESC with vG4Nk or vGTM induces cardiac gene expression 
In order to examine gene expression changes resulting from transduction with the vG4Nk vector, 
mESC were mock infected or infected with vGFP or vG4Nk at 2 pfu/cell (roughly 800 gc/cell) 
for 1.5 h in suspension. Cells were plated in 6 well plates without LIF, and RNA was collected at 
0, 24, 48, and 72 hpi and reverse transcribed for qRT-PCR, with mouse heart cDNA as a positive 
control for expression of mouse cardiac genes. Expression of transgenic (human) and 
endogenous (mouse) GATA4 and NKX2.5 was examined in vG4Nk-infected mESC compared to 
control vector vGFP-infected mESC. Strong expression of the two human transgenes was 
detected in vG4Nk-infected cells at 24 hpi. Transgene expression dropped off sharply between 
24 and 48 hpi, although GATA4 and NKX2.5 transcripts remained detectable through 72 hpi. As 
expected, expression of the human transgenes was not detected from vGFP-infected mESC 
(Figure 35A). While expression of human GATA4 fell dramatically after 24 h from vG4Nk-
infected mESC, expression of endogenous Gata4 increased from 24 h to at least 72 h post mESC 
infection with vG4Nk, but only barely from vGFP-infected mESC. There was a similar but 
smaller increase in expression of endogenous Nkx2.5 from mESC infected with vG4Nk 
compared to mESC infected with the control vector (Figure 35B). 
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Figure 35. Expression of GATA4 and NKX2.5 in vGFP- and vG4Nk-infected mESC as determined 
by qRT-PCR 
mESC were infected with either vGFP or vG4Nk, and qRT-PCR was used to examine expression of 
human (transgene) (A) and mouse (endogenous) (B) GATA4 and NKX2.5 24, 48, and 72 hpi.  
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Next we used qRT-PCR to determine the expression levels of GATA4- and NKX2.5-
responsive genes typically expressed early in the cardiac differentiation process (Table 1), 
Tbx20, Gata6, Myocd, and Foxa2 (136, 181), from vG4Nk-infected mESC relative to vGFP- and 
mock-infected mESC. Of the 4 genes examined, Gata6 and Foxa2 showed the greatest response 
to transduction with vG4Nk. Both Gata6 and Foxa2 expression were greater at all three time 
points from vG4Nk-infected cells than vGFP- or mock-infected cells, and the levels of both 
transcripts increased continuously over the first 72 hpi (Figure 36). Expression of Tbx20 was 
increased 5-fold from vG4Nk-infected mESC at 24 hpi compared to vGFP-infected mESC, and 
expression of Myocd was increased 10-fold. However at 3 dpi, expression of these two genes 
from the control cells had caught up with that from the experimental vector-infected cells (Figure 
36). Together, these results suggested that vector-mediated GATA4 and Nkx2.5 expression 
increases the induction kinetics of early cardiac-related genes in mESC following LIF 
withdrawal.  
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Figure 36. Expression of GATA4- and NKX2.5-responsive genes in vG4Nk-infected mESC as 
determined by SYBR Green qRT-PCR 
mESC were infected with vGFP, vG4Nk, or mock-infected. qRT-PCR was used to compare the 
expression of selected GATA4-responsive genes between the three conditions at 24, 48, and 72 hpi. 
mRNA levels were normalized to 18S rRNA and are expressed relative to day 0 uninfected mESC. Data 
for Tbx20 and Myocd are displayed on a logarithmic scale while Gata6 and Foxa2 are displayed on a 
linear scale. 
 
 
 
We next examined transgene expression and the expression of transgene-responsive 
endogenous genes in differentiating EB. mESC were infected in suspension with 2 pfu/cell of 
vGFP, vG4Nk or vGTM, or were mock infected, and the cells were dispensed into hanging drops 
for EB formation. RNA was collected 24, 48, and 72 hpi and reverse transcribed for qRT-PCR. 
Similarly to experiments described above, GATA4 and NKX2.5 transgenes were expressed 
robustly at 24 hpi in EB made from vG4Nk-infected mESC (vG4Nk EB), and their mRNAs 
could be detected for at least 72 h after the onset of differentiation. GATA4 was expressed at 
similar levels in EB from vGTM-infected mESC (vGTM EB), and its expression also remained 
detectable for at least 72 h after infection and the start of differentiation (Figure 37A). 
Endogenous Gata4 expression was upregulated for at least 48 hpi from vG4Nk EB, and for at 
least 72 hpi from vGTM EB compared to EB from mock- (Ø EB) or vGFP-infected mESC 
(vGFP EB). Interestingly, while endogenous Nkx2.5 did not appear to be upregulated from 
vG4Nk EB, its expression from vGTM EB was higher at 72 hpi than at earlier times or from any 
of the other EB at 72 hpi. Sox17, a gene previously shown to be upregulated by GATA4 (181), 
was expressed at increasing levels over the first 72 hpi from both vGTM EB and vG4Nk EB, 
each greater than in Ø EB or vGFP EB. (Figure 37B).  
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Figure 37. Expression of GATA4 and Nkx2.5 transgenes and endogenous genes in EB determined 
by TaqMan qRT-PCR 
mESC were infected with vGFP, vG4Nk, vGTM or mock-infected. TaqMan qRT-PCR was used to 
examine expression of transgenes and endogenous genes from EB at 24, 48, and 72 hpi. mRNA levels 
were normalized to HPRT and are presented relative to the levels in vGFP EB at 24 hpi (A) or uninfected 
mESC (B). (A) Expression of human GATA4 in vG4Nk EB or vGTM EB (left) and of human NKX2.5 in 
vG4Nk EB. (B) Relative expression of endogenous cardiomyogenic genes Gata4, Nkx2.5, and Sox17. 
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Lastly we sought to examine the effects of transduction with vG4Nk and vGTM on gene 
expression in differentiating EB at later times post infection. mESC were infected with 3000 gc 
(~ 5 pfu)/cell of the three JΔNI8 vectors and differentiated by EB formation in hanging drops. 
RNA was extracted at 3 dpi for the first time point, and the remaining EB were plated in 48 well 
plates for attachment, outgrowth, further differentiation, and RNA extraction at 6 and 9 dpi. 
RNA was reverse transcribed and gene expression levels were determined by qRT-PCR. While 
human GATA4 transgene RNA was detectable for at least 9 dpi from both vG4Nk EB and vGTM 
EB, upregulation of endogenous Gata4 was only seen at 3 dpi. At later time points, endogenous 
Gata4 levels were similar to those from Ø EB and vGFP EB. Gata6 appeared to be slightly 
upregulated from d3 vG4Nk EB and vGTM EB, but expression levels from Ø EB vGFP EB were 
higher at both 6 and 9 dpi. Similarly, Sox17, Foxa2, and Myo5b were upregulated on day 3 from 
vG4Nk EB and vGTM EB, but by 6 dpi these genes were expressed at levels comparable to 
those from Ø EB and vGFP EB (Figure 38). Taken together, the results from these experiments 
suggested early but transient upregulation of endogenous cardiac genes by vector-mediated 
expression of human GATA4 and Nkx2.5. Experiments in the next section were performed to 
determine whether these early changes might influence the efficiency of cardiomyocyte terminal 
differentiation.  
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Figure 38. Longer term cardiac gene expression from infected mESC-derived EB 
Gene expression at 3, 6, and 9 dpi in EB from mESC transduced with vGFP, vG4Nk, or vGTM, or 
uninfected mESC as determined by SYBRgreen qRT-PCR. Expression was normalized to 18S rRNA 
(human and mouse GATA4) or HPRT (Foxa2, GATA6, Myo5b, and Sox17) RNA, and is presented 
relative to uninfected, undifferentiated mESC. 
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5.3.7 Transduction of mESC with vG4Nk or vGTM prior to differentiation in 
combination with temporary inhibition of cell division increases the population of EB 
showing spontaneously contracting patches 
To determine whether vG4Nk infection of mESC prior to the onset of differentiation could 
increase the percentage of EB with visibly contracting cardiomyocytes, mESC were infected 
with vGFP or vG4Nk at 2 pfu/cell, or mock-infected. As before, cells were aggregated in 
hanging drops immediately after infection for differentiation in EB. EB were plated at 3 dpi, one 
per well in 48 well plates for attachment and outgrowth. EB were examined daily for the 
appearance of spontaneously contracting cardiomyocytes. Visible cardiomyocytes first appeared 
8 d past the onset of differentiation, and initially there was a greater percentage of contracting 
vG4Nk EB than Ø EB or vGFP EB. However, between days 8 and 10, the percentage of EB 
containing visible cardiomyocytes became equal between the three conditions (Figure 39A). This 
differentiation experiment was repeated several times with similar results (data not shown).  
In order to prolong the persistence of viral genomes in differentiating EB, we explored 
the use of cytosine β-D-arabinofuranoside (Ara-C) to temporarily inhibit cell division and 
diminish the initial rate of HSV genome dilution. To determine the appropriate Ara-C 
concentration to delay cell division without toxicity, we treated cells with 0 – 10 μM Ara-C, 
replacing the media and counting cells in duplicate wells each day for 4 d. While 1 μM Ara-C 
appeared to be toxic to mESC, causing the number of cells to decrease from 0 to 4 d, cell 
division still occurred with 0.1 μM Ara-C (Figure 39B).  We chose an intermediate concentration 
of 0.3 μM Ara-C for the next differentiation experiment.  
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Figure 39. Cardiomyocyte appearance in vG4Nk EB and Ara-C titration on mESC 
(A) mESC were infected with vGFP, vG4Nk, or mock, and EB were plated at 3 dpi. The percentage of 
spontaneously contracting EB was counted each day from 4 – 10 dpi. (B) Ara-C was titrated on mESC 
with concentrations from 0 – 10 μM and the number of cells was counted each day. 
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In the next differentiation experiment, we included vGTM to examine its ability to 
influence cardiomyocyte formation. mESC were infected in suspension with 2000 gc/cell of 
vGFP, vG4Nk, or vGTM, or were mock-infected. Cells were diluted in media containing 0.3 μM 
Ara-C and transferred into hanging drops to allow aggregation into EB. Because cell division 
was inhibited by Ara-C, 4000 cells were dispensed per 30 μl drop instead of the typical 800 
cells/20 μl drop. EB were allowed to differentiate in hanging drops for three days, then plated 
one per well in 48 well plates for attachment and outgrowth. This experiment was repeated three 
times, and the results for each individual experiment can be seen in Figure 40A. Because of 
variability in the time to first appearance of visibly contracting cells between the three 
experiments, as well as differences in the percentages of contracting EB at each data point, the 
error surrounding the average value for the three experiments combined is high (data not shown). 
However there is a clear trend that spontaneously contracting cardiomyocytes appeared sooner in 
Ara-C-treated vG4Nk EB and especially with vGTM EB than in similarly treated Ø EB or vGFP 
EB. Moreover, the percentage of contracting EB was greater at almost every time point for 
vG4Nk EB or vGTM EB (Figure 40B). Taken together, these three experiments clearly indicated 
that infection of a small number of stem cells with vG4Nk or vGTM has long reaching effects on 
the mESC differentiation program even when the virus genomes have been drastically diluted as 
the cells divide over a period of 12 days. 
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Figure 40. Contracting Ø, vGFP, vG4Nk, and vGTM EB with Ara-C treatment 
mESC were infected with vGFP, vG4Nk, vGTM, or mock infected, and treated with 0.3 μM Ara-C for 
the first 48 h of differentiation in EB. (A) The results of three independent experiments (left, center, and 
right) showing the percentage of EB containing visible cardiomyocytes. (B) The averages of the 
independent experiments from (A). 
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5.4 DISCUSSION 
In this chapter, we describe the engineering and use of two JΔNI8-based vectors to influence 
mESC to differentiate toward a cardiac cell fate. Two highly replication defective HSV vectors, 
vG4Nk and vGTM, were created through BAC recombineering to express polycistronic 
transgene cassettes of cardiac-specific transcription factors separated by 2A “ribosomal 
skipping” sequences. The JΔNI8 backbone contains numerous gene deletions, including ICP4, 
ICP27, ICP0, ICP47, UL41, and the entire joint region of the HSV genome; the modified 
promoter of the remaining IE gene, ICP22, is inactive in the absence ICP4. Transgene cassettes 
were expressed from the LAT locus in both vG4Nk and vGTM. This region of the HSV genome 
contains LAP2, which can act as a long-term enhancer element for transgene expression (173). 
The LAT locus is also protected from viral genome silencing during latency by regions rich in 
CTCF binding sites called CTRLs. Unlike JDββHE-based vectors, these JΔNI8-based vectors 
express no ICP0, and the transgenes are expressed from a protected locus, so they are able to 
efficiently transduce many cell types without detectable toxicity (169). 
vG4Nk and vGTM are both capable of growing to high titers and efficiently transducing 
mESC. Both GATA4 and NKX2.5 proteins were detected in vG4Nk-infected D3 mESC by 
Western blotting. Likewise, GATA4, TBX5, and MEF2C were detected in vGTM-infected 
mESC by Western blotting. Expression of eGFP was clearly visible in both vG4Nk- and vGTM-
transduced mESC and U2OS cells.  
qRT-PCR experiments with species-specific primers and probes demonstrated that 
GATA4 transgene expression from vG4Nk EB and vGTM EB could be detected for at least 9 dpi. 
Transduction of mESC with either of these two vectors induced the expression of endogenous 
genes that play a vital role in cardiogenesis, including Gata4, Sox17, Foxa2, and Myo5b, for at 
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least 3 dpi. While vG4Nk was more efficient than vGTM at inducing endogenous Gata4 
expression in transduced mESC, both vG4Nk and vGTM performed similarly to induce the 
expression of the other transgenes examined.  
Initially, transduction of mESC with neither vG4Nk nor vGTM increased visible 
cardiomyocyte differentiation in EB. However, when Ara-C was used to inhibit cell division for 
48 hpi, significantly more vG4Nk EB and vGTM EB contained spontaneously contracting 
patches of cardiomyocytes than Ø EB or vGFP EB. As with previous similar experiments, there 
was significant variability in the absolute percentages of EB with contracting cardiomyocytes 
between replicates. However, the trend remained consistent that between 4 – 6 times more 
vG4Nk EB and vGTM EB mESC contained visible cardiomyocytes than Ø EB or GFP EB. 
The results in this chapter demonstrate that both vector vG4Nk and vector vGTM 
efficiently deliver transgenes for cardiac transcription factors to mESC at low MOI and with no 
overt toxicity. Expression of GATA4 and NKX2.5 or GATA4, TBX5, and MEF2C proteins from 
these vectors induced expression of target genes involved in cardiomyogenesis. Transduction of 
mESC with vG4Nk and vGTM followed by EB differentiation of transduced cells had a positive 
impact on cardiomyocyte differentiation for as long as 12 dpi. These promising results suggest a 
number of possible future directions. Microarray or RNA-Seq technology could be used to 
capture a snapshot of how transduction of stem cells with these vectors affects gene expression 
more globally. As discussed in section 4.5, differentiating mESC in EB has both advantages and 
disadvantages. EB provide a three dimensional structure that mimics a developing embryo and 
fosters cell-cell interactions that are important for certain developmental programs, but the 
generation of cytokines and other factors within the EB can make experimental interpretation 
and reproducibility difficult. We might want to explore alternative methods to differentiate 
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mESC that may be more amenable to cardiac development, for example differentiation in a 
monolayer or differentiation entirely in suspension. It would also be useful to examine 
expression of cardiac-specific proteins in differentiated cells using flow cytometry and/or 
immunofluorescence and confocal microscopy to gain a better understanding of the magnitude of 
the increase in cardiomyocyte differentiation achieved using vectors vG4Nk and vGTM. To this 
end we engineered a cardiac reporter cell line with the cardiac-specific α-MHC promoter driving 
expression of eGFP. The reporter construct functioned flawlessly at first, as evidenced by all 
contracting cells in EB displaying green fluorescence, but after several passages under 
continuous antibiotic selection, the cells lost their reporter function.  
The cardiac transcription factors GATA4, TBX5, and MEF2C in vGTM were originally 
chosen because this combination was successfully used to transdifferentiate fibroblasts into 
cardiomyocytes both in vitro (143) and even more successfully in vivo (144). The in vivo work 
was completed in the mouse model of MI, and a combination of retroviruses encoding each 
transcription factor was injected directly into the infarcted area of the heart. Cardiac fibroblasts 
directly transdifferentiated into cardiomyocytes. Significant improvements in heart function and 
reduced scarring were observed. However, retroviruses integrate into host cell chromosomes 
with potential oncogenic effects stemming from insertional mutagenesis. Although beyond the 
scope of this current work, in vivo use of vGTM for MI repair has great potential without the 
concerns associated with the use of retroviruses.  
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6.0  SUMMARY AND CONCLUSIONS 
Ischemic heart disease is one of the leading causes of morbidity and mortality worldwide(22). 
The mammalian heart lacks the ability to repair itself (23), and drug-based therapies cannot 
replace functional cardiac tissue. Cell-based therapy is viewed by many as the most promising 
approach to improve the prognosis of patients suffering from diseases of the heart. In this work, 
we sought to enrich the population of mature, beating cardiomyocytes derived from PSC in two 
distinct ways: 
1. Creating a mESC line to constitutively overexpress GATA4 
2. Using replication defective HSV vectors to deliver combinations of key 
cardiogenic transcription factors to mESC  
GATA4 is a cardiac-specific transcription factor that is vital for cardiomyogenesis and 
cardiac function from the earliest days of embryonic development through adulthood (13). We 
described the generation of a mESC line to constitutively express high levels of the human 
GATA4 protein (D3G4). Nucleofection was used to stably transfect D3 mESC with a GATA4 
cassette containing the puromycin resistance gene for selection. Multiple clonal lines were 
generated. One line expressed high levels of GATA4 protein and was dramatically enriched for 
cardiomyocyte differentiation compared to a control eGFP-expressing cell line. Expression of 
cardiac-specific genes Gata4, Nkx2.5, cTnI, and Mlc2a was increased by up to two orders of 
magnitude in d12 D3G4 EB compared to d12 eGFP EB. These data suggest that constitutive 
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GATA4 overexpression is a powerful driver of in vitro cardiac differentiation in mESC. 
However the use of a stably transfected cell line to overexpress GATA4 is not a clinically viable 
model for generating cardiomyocytes for transplant. The possibility of undesirable second-site 
effects and the increased oncogenic potential of cells with permanent chromosomal 
modifications make them unsafe for therapeutic cell-based treatments in humans.  
Next we sought to determine if transient expression of GATA4 in combination with 
additional cardiogenic genes NKX2.5 or TBX5 and MEF2C from non-integrating replication-
defective HSV vectors could similarly push mESC toward a cardiac lineage. Cardiac vectors 
vββG4Nk, vG4Nk, and vGTM were each used to transduce mESC prior to differentiation. EB 
derived from cells transduced with these vectors demonstrated increased expression of 
endogenous genes vital for cardiomyogenesis and cardiac function over those transduced with 
control vectors. At different times post-infection, Gata4, Nkx2.5, Foxa2, Gata6, Tbx20, 
Myocardin, Sox17, Mlc2a, Myo5b, and cTnI expression were induced by cardiac vector 
transduction. Upregulation of several cardiac genes continued after transgene expression could 
no longer be detected. Transduction of mESC with each of the three cardiac HSV vectors, 
vββG4Nk, vG4Nk, and vGTM, increased the cardiac potential of the cells upon differentiation in 
EB. vββG4Nk, vG4Nk, and vGTM EB contained significantly more spontaneously beating 
cardiomyocytes than EB derived from mESC transduced with control vectors.  
The overall findings of this dissertation research suggest that HSV vectors can be a useful 
tool for producing lineage related changes in differentiating pluripotent stem cells to generate 
specialized cell types. HSV vectors have many advantages over other gene delivery systems, 
including a large payload capacity, the ability to express transgenes in many different cell types, 
and, unlike retro- and lentiviral vectors, viral genomes remain episomal, mitigating concerns 
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over insertional mutagenesis. Moving forward, in vivo use of vGTM for reprogramming 
fibroblasts into cardiomyocytes in a study similar to that from Qian et al. would be an exciting 
next step (144). Achieving reprogramming through the use of non-integrating HSV vectors 
would provide a safe alternative to the original study, and represents a promising potential 
translational therapy for cardiac ischemia. 
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